Development of Methods and Applications to Clinical Data by Pettersson, Niclas
Modelling Late Toxicity in Hypofractionated Radiation Therapy
Development of Methods and Applications to Clinical Data
Niclas Pettersson
Department of Radiation Physics, University of Gothenburg
Gothenburg, Sweden 2013
Doctoral Thesis, 2013
Department of Radiation Physics
University of Gothenburg
Sahlgrenska University Hospital
SE-413 45 Göteborg
SWEDEN
Copyright © 2013 Niclas Pettersson (pages I-60)
ISBN: 978-91-628-8647-9
E-publication: http://hdl.handle.net/2077/32036
Printed in Sweden by Kompendiet
 
Datta: what have we given? 
My friend, blood shaking my heart 
The awful daring of a moment’s surrender 
Which an age of prudence can  never retract 
By this, and this only, we have existed 
Which is not to be found in our obituaries 
Or in memories draped by the beneficent spider 
Or under seals broken by the lean solicitor 
In our empty rooms
  T.S. Eliot, The Waste Land (1922)

VABSTRACT
In hypofractionated radiation therapy (RT), the treatment is delivered by few fractions with high doses per fraction. This is in contrast to conventionally fractionated RT where the 
total dose is delivered in many fractions with low doses per fraction. Hypofractionation is 
increasingly used in RT for small tumour volumes, but knowledge about radiation-induced tox-
icity in healthy tissue (organs at risk, OARs) and suitable methods for modelling toxicity in this 
specific situation is limited. The aim of this thesis is to investigate radiation-induced toxicity in 
normal tissue caused by hypofractionated RT through the development of modelling methods 
and their applications to clinical data. Particular emphasis will be on the fractionation effect.
The thesis treats theoretical and practical aspects of normal tissue complication probability 
(NTCP) modelling such as radiobiologically consistent dose-response curves, how to estimate 
composite doses in combined radiation therapy with limited treatment information and how 
to manage situations where non-treatment-related factors contribute to a studied toxicity. The 
thesis also discusses how fractionation effects as described by the linear-quadratic model may 
affect the modelling procedure and the modelling results. The clinical applications involve two 
datasets with non-small-cell lung cancer (NSCLC) patients (n=26) or localized prostate cancer 
patients (n=874). Patients were consecutively treated at the Sahlgrenska University Hospital in 
Göteborg, Sweden, 1998-2005 and 1993-2006, respectively.
The first paper presents NTCP modelling results for radiation-induced rib fractures after hypo-
fractionated SBRT for NSCLC. The results indicate that the high-dose region is more strongly asso-
ciated with rib fracture than a low dose in a large volume.
The second paper presents a survey of 21 patient-reported genitourinary symptoms among 
prostate cancer survivors. The toxicity profile for survivors treated with the combination of 
conventionally fractionated external beam radiation therapy (EBRT) and hypofractionated 
brachytherapy (EBRT+BT) is similar to the toxicity profile for survivors treated with convention-
ally fractionated EBRT. 
The third paper investigates urethral pain among prostate cancer survivors and finds that higher 
fractionation-corrected urethral dose corresponds to higher prevalence; no such relationship is 
seen for absorbed dose. Survivors with three years to follow-up report urethral pain more fre-
quently than survivors with more than three years to follow-up. 
The fourth paper suggests a method to estimate composite doses in pelvic OARs after prostate 
cancer EBRT+BT with limited treatment information. It was motivated by the lack of BT dose 
information in the prostate cancer dataset. The method produces robust estimations for OARs 
located far from the prostate, but estimations for OARs located close to the prostate may be less 
robust.
The fifth paper presents a relationship between mean urinary bladder dose (with or without frac-
tionation correction) and urinary leakage for men treated with EBRT. Analyses are performed for 
survivors treated with EBRT and EBRT+BT separately as well as for the whole study population. 
Symptom background rates from non-irradiated controls were considered. Estimated composite 
urinary bladder doses by the method suggested in Paper IV are used for the EBRT+BT group.
Keywords: hypofractionation, normal tissue complication probability, modelling, linear-quadratic model, 
fractionation sensitivity, late toxicity, radiation-induced rib fracture, genitourinary toxicity, stereotactic 
body radiation therapy, high-dose-rate brachytherapy, multimodality radiation therapy, patient-reported 
outcomes, prostate cancer, NSCLC.
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11. INTRODUCTION
1.1 Background
Today, more than 6 million individuals worldwide receive radiation therapy as part of their cancer treatment each year [1, 2]. The ideal radiation therapy is one 
where there is a sufficiently high dose to eradicate the tumour and no dose at all else-
where to avoid unwanted effects in healthy tissue. This is however not a practically 
achievable dose distribution, and our everyday clinical task is to arrive at the best com-
promise where each patient’s treatment plan has a high probability of eliminating the 
tumour while simultaneously having a low risk of damaging the surrounding non- 
malignant tissues. The field of radiation therapy has the previous decades undergone 
considerable technological developments in patient imaging, treatment planning and 
delivery and we now have better means to create and deliver suitable dose distributions.
The process of treatment planning consists of three major parts. First, the patient is 
imaged using one or more three-dimensional (3D) imaging techniques such as com-
puted tomography (CT), magnetic resonance imaging (MRI) or ultrasound imaging. 
Second, on these images, the volumes suspected to contain microscopic and macro-
scopic tumour tissues, and the organs we do not want to irradiate (organs at risk, OARs) 
are identified. In the third step, the treatment plan is created by optimizing how the 
dose will be distributed within the patient, i.e. how much dose that should be received 
by the tumour and how much the dose to the healthy organs should be restricted. The 
results of the treatment planning procedure are a 3D dose distribution, the absorbed 
dose calculated in a large number of volume elements (voxels) inside the patient,and the 
corresponding treatment machine settings required to deliver this dose distribution in 
the patient. Absorbed dose is, however, a physical quantity that describes the amount 
of energy from ionizing radiation absorbed per unit mass and is seldom linearly related 
to the biological effect in human tissue. Thus, for each treatment regimen we must not 
only optimize the dose distribution, but also how much dose that should be delivered 
at each treatment (fraction) to achieve the desired outcome. This optimization is a 
compromise between our competing objectives of tumour elimination and unwanted 
effects in normal tissue.
To deliver the planned dose to the tumour and surrounding tissue at each fraction, the 
patient needs to be immobilized in an accurate and reproducible position relative to the 
treatment machine. Current developments of patient positioning techniques involve 
X-ray imaging and adjustment immediately prior to treatment; this increases the corre-
spondence between the planned and delivered absorbed dose distributions in both the 
tumour and surrounding OARs [3].
21.2 Fractionation
Early in the 20th century it was recognized that delivering the same amount of ioniz-
ing radiation in a large number of fractions during a longer period of time resulted in 
reduced normal tissue effects [4]. However, for many decades there were conflicting 
interpretations regarding if this was due to a time effect, a dose per fraction effect or a 
combination of both [4]. The relationship between overall treatment time (OTT), total 
dose, and dose per fraction was not understood until the late 1970’s and early 1980’s 
[5-7]. The response to altered fractionation for both normal and tumour tissue was 
then mathematically described by the linear-quadratic (LQ) model [5, 8]. This model 
was derived from the concept of cell-survival curves: the proportion of cells surviving 
irradiation is described with two parameters, α and β. The quotient, α/β, is the quan-
tification of the tissue’s fractionation sensitivity and if this quotient is known one can 
calculate the effect of a change in dose per fraction. Delivering the same total dose in a 
large number of fractions results in reduced normal tissue toxicity. However, the daily 
fraction dose cannot be arbitrarily small since this will lead to a very long OTT which in 
turn becomes a problem due to accelerated tumour repopulation [9, 10]. The model has 
also been used to design many clinical studies [11].
The LQ model was further developed to recognize other factors such as OTT, dose rate, 
low-dose hypersensitivity, and incomplete repair between fractions [12]. It is the model 
most widely utilized in the clinic today and, given knowledge on the relevant parame-
ters, it can be expected to give results in line with observed clinical data when the dose 
per fraction is between 1 and 6-8 Gy. Until now, most treatments have been delivered 
using around 2 Gy per fraction, and the knowledge about how tumour and normal 
tissues respond to high doses per fraction is limited. There is currently a debate on 
whether the LQ model accurately describes the fractionation effect at large doses per 
fraction and several competing models have been suggested [13-18].   
1.3 Complications and normal tissue 
complication probability
Unwanted radiation-induced toxicity, side effect, in normal tissue has always been an 
inherent risk of radiation therapy. As our treatment techniques have improved over 
time with regards to the irradiation of normal tissue, we have gradually learned to 
avoid the most debilitating complications. This has given us possibility to identify and 
deal with toxicity that may be considered ‘less severe’ but could be detrimental to the 
patient’s quality of life. In this regard, patient-reported outcomes (PROs) are becoming 
an important supplement to more traditional assessments and scoring of toxicity [19].
In the early 1990’s, Emami and co-workers made one of the first efforts to compile avail-
able data and present them in a form suitable for implementation in everyday clinical 
work [20]. They suggested dose levels for 5% and 50% risk of complication for various 
OARs and toxicities. Specifically, they used a ‘volume parameter’ to quantify how sensi-
tive the OAR was to a change in irradiated volume – the volume effect. This meant that 
they had a normal tissue complication probability (NTCP) model i.e. a link between an 
inhomogeneously irradiated OAR and the risk of complication [21, 22]. Many such NTCP 
3models have been proposed over the years [23-29]. Regardless of their different aspira-
tions on being biologically founded, they are all similar in that they consider how the 
total dose, the dose per fraction and the amount of irradiated volume affect the risk of 
complication.
To fit an NTCP model to clinical data, we need to collect information from a cohort of 
patients. Specifically, we need data on whether the patient experienced a complication 
and a description of the dose distribution from the organ(s) we suspect the complica-
tion originates from. Furthermore, organs can express radiation damage in several dif-
ferent ways and each of those must be separately modelled. The ideal situation for NTCP 
modelling is to measure a specific toxicity – an atomized symptom – and to be certain 
from which OAR the damage originates [30]. Once the best model (and its model param-
eters) has been determined, it can assist in creating treatment plans with lower risks of 
complication.
1.4 Hypofractionation
Hypofractionation is the use of few fractions with a high dose per fraction. The tumour 
dose delivered at each fraction must be at least 2.5 Gy* and should be delivered in less 
than 20-30 minutes. There are many ways to optimize fractionation regimens and 
some or all fractions can be delivered with a high dose for the regimen to be considered 
hypofractionated. There are some obvious advantages with hypofractionation, from 
both the clinical and the patient’s perspective. It uses less time on expensive and maybe 
scarce resources in the radiation therapy department, it is more convenient for the 
patient since there are fewer fractions, and there may sometimes be radiobiological ben-
efits such as the short OTT leaving little time for accelerated tumour repopulation.
However, fractionation regimens with high dose per fraction have historically been 
associated with increased normal tissue complications [31]. This association originates 
from treatments during the 1940’s – 1980’s when some regimens were developed using 
incorrect models [4, 32]. In addition to the large volumes of irradiated normal tissue 
during that period, these regimens failed to properly take the fractionation effect for 
normal tissue into account. The total dose was not sufficiently decreased to compensate 
for the increased effect at high doses per fraction and this sometimes resulted in severe 
complications [33].
1.4.1 Modern hypofractionated techniques
Technological advances in radiation therapy techniques in the 1980’s and 1990’s brought 
image-based treatment planning, multi-leaf collimators (MLCs) and novel ways to 
make sure the patient (and the tumour) was correctly positioned on the treatment table. 
This enabled us to create and deliver dose distributions with a considerably decreased 
volume of irradiated tissue outside the tumour. The combination of highly conformal 
dose distributions and a better insight in fractionation sensitivity are now creating new 
possibilities for hypofractionated treatments. Two techniques that make use of this are 
stereotactic (body) radiation therapy and brachytherapy (BT).
* No universally adopted definition of hypofractionation exists, but the dose per fraction should be notably 
larger than the 2-Gy fractions used in conventional fractionation.
41.4.2 Stereotactic (body) radiation therapy
Stereotactic radiation therapy (SRT) is an external beam radiation therapy (EBRT) tech-
nique that is utilized to irradiate small tumours or lesions. Special equipment is used to 
ensure that an accurate relationship between the patient’s anatomy and the coordinate 
system of the treatment machine can be established. The treated lesions are preferably 
small, the patient is carefully set-up in the dedicated system, and a multi-leaf collima-
tor with small leaf width is usually used. The resulting dose distributions are exception-
ally conformal, but the treatment set-up procedure is time-consuming. The use of fewer 
fractions is thus both a possibility and a practical necessity.
SRT was initially used to treat intracranial tumours and non-malignant, malfunctioning 
vascular bundles (arteriovenous malformations, AVMs). In the latter case the objective 
was to obliterate the AVM by creating a necrosis, i.e. the normal tissue ‘complication’ is 
in this case the sought treatment effect.
Stereotactic body radiation therapy (SBRT) was introduced in the 1980’s. It uses simi-
lar principles as SRT, but is applied outside the cranium [34]. So far, most experience in 
SBRT has been gained for liver and lung tumours, but results for prostate treatment tech-
niques are emerging as well [35]. The rationale behind hypofractionated liver and lung 
SBRT, besides the poor outcomes for conventional fractionation, was that both organs 
were considered to tolerate high doses in small volumes [36].
1.4.3 Brachytherapy
BT is the treatment of malignant disease by means of placing a radioactive source close 
to or inside the tumour. The primary advantage of BT is the rapid dose fall-off outside 
the high-dose region resulting in less volume of normal tissue being irradiated. Radi-
oactivity was discovered in 1896, and already as early as in the first decade of the 20th 
century radium (226Ra) was utilized in efforts to treat tumours. For a long time, manual 
placement of the radioactive source was performed which led to unnecessary irradiation 
of the hospital staff. To overcome this problem, BT treatment machines – afterloaders – 
were developed in the 1960’s. In an afterloader, the radioactive source is welded to the 
end of a wire. The afterloader is connected to one or many catheters placed in or close 
to the tumour and the position of the wire within each catheter can then be remotely 
operated. This leads to radiation protection for the staff, and by placing the source at dif-
ferent positions within the fixed catheters for different durations, the dose distribution 
can also be optimized. There are many ways to deliver BT, and the time it takes to deliver 
a treatment varies greatly from months in permanent implantations with iodine (125I) or 
palladium (103Pd) sources to minutes in high-dose rate (HDR) BT with sources of cobalt 
(60Co) or iridium (192Ir).
Current state-of-the art BT is an image-guided and intensity-modulated treatment 
modality where current interests and developments mainly are focused at cervical and 
prostate cancer [37, 38]. The reason for using hypofractionation in BT is simple: placing  
catheters within a deep-seated tumour is an invasive and time-consuming procedure 
and maximum benefit should be gained from each session. Using BT in combination 
with image-guided techniques, a highly conformal tumour dose distribution taking 
normal tissue irradiation into account can be achieved.
51.5 Aim of the thesis
Although several hundred papers on quantification and modelling of complications 
after radiation therapy are published each year, knowledge about normal tissue toxicity 
after hypofractionated radiation therapy is limited. It is indicative that the compilations 
of normal tissue tolerance doses suggested by Emami et al. in 1991 and the follow-up 
effort by QUANTEC in 2008 mainly dealt with conventional fractionation [20, 39, 40]. 
Hypofractionated radiation therapy is today an established technique to deliver cura-
tive radiation therapy and more knowledge about how radiation-induced effects arise is 
essential to improve treatments for future patients.
The work described in this thesis aims to investigate normal tissue complications in 
hypofractionated radiation therapy through the development of methods and their 
application to clinical data. In particular, the objectives are:
 ◆ to derive a dose-response curve for treatments delivered with a fixed 
number of fractions where the fractionation effect is taken into 
account,
 ◆ to apply the derived dose-response curve in NTCP modelling of radi-
ation-induced rib fractures following hypofractionated SBRT for non-
small-cell lung cancer,
 ◆ to investigate relationships between urethral doses and urethral pain 
in conventionally and hypofractionated radiation therapy for pros-
tate cancer,
 ◆ to develop a method to estimate composite doses in combined EBRT 
and BT when image and dose information for BT is lacking, and
 ◆ to use composite doses and information from a non-treated popula-
tion in NTCP modelling of genitourinary toxicity after prostate can-
cer radiation therapy.

72. BACKGROUND
In NTCP modelling the aim is to determine a relationship between the delivered dose distribution in a volume of normal tissue and a specific toxicity that originates from 
that same tissue. The mathematical formulation of this relationship is called an NTCP 
model and included in this formula are model parameters that are specific to each com-
bination of OAR and studied toxicity. The minimum requirements needed to establish 
the relationship, i.e. to determine the model parameters, are a description of the deliv-
ered dose and a systematic evaluation of the toxicity of interest in a cohort of patients. 
Once the model and its parameters are known, it can guide us in the treatment plan-
ning process to minimize the risk of this complication for future patients.
There are typically three tissue- and toxicity-specific OAR properties that we want to 
consider for a risk of radiation-induced complication: the effect of the total dose, the 
effect of the dose per fraction and the effect of different dose distributions within the 
OAR. The mathematical structure of NTCP models consider this and the determined cor-
responding parameter values will reflect the tissue properties. Calculating the NTCP for 
a given dose distribution typically consists of two steps: first, the 3D OAR dose distribu-
tion is summarized into a single representative value, and second, this representative 
value is used to calculate the probability of a given complication.
There are two concepts of tissue response that have been proposed and that are relevant 
for the feasibility of hypofractionated radiation therapy. A serial-type tissue is thought 
of as having subvolumes organized in a chain-like structure and damaging one small 
part has adverse effects on the overall function of the tissue [41]. For serial-type tissues, 
it is the highest dose that mainly determines the risk of complication. In contrast, the 
function of a parallel-type tissue is the sum of contributions from each subvolume and 
damaging one small part will have little effect for the overall response. For parallel-type 
tissues, the dose averaged over all subvolumes (the mean dose) mainly determines the 
risk of complications. The concepts of serial-type and parallel-type tissue are closely 
related to the volume effect. A tissue that is insensitive to changes in mean dose is said 
to have a small volume effect and vice versa. Examples of serial and parallel tissues are 
the spinal cord and lung, respectively.
2.1 Fractionation in radiation therapy
2.1.1 The linear-quadratic model and survival curves
The LQ is model used as a means to quantify the surviving proportion of irradiated 
tumour cells [41]. The change in the surviving fraction (SF) of tumour cells with dose is 
described by the equation
SF(d)=e−(αd+βd2) (2.1)
where α (Gy -1) and β (Gy -2) are parameters quantifying the radiation sensitivity, and 
8d is the absorbed dose. α/β describes the shoulder of the survival curve when plotted 
in a linear-logarithmic diagram (Figure 2.1, solid curves). When the quotient is small, 
cells are more sensitive to changes in the dose per fraction, i.e. they have a larger frac-
tionation sensitivity. If the time between two irradiations is sufficiently long, it can be 
assumed that all repairable damage inflicted by the first irradiation has been completely 
repaired, and a new cell survival curve can be superimposed on the first. According to 
the LQ model, the surviving proportion of cells after n fractions (all of dose d) will be
SF(D)=[e−(αd+βd2)]n=e−(αnd+βnd2)=e−(αD+βdD) (2.2)
where the total absorbed dose D is given with n fractions, each of absorbed dose d 
(Figure 2.1, dashed curves) [41].
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Figure 2.1. Survival curves for two different α/β delivered in a single fraction (solid curves) or in 2-Gy 
fractions (dashed curves). Top: α/β=3 Gy, bottom: α/β=10 Gy.
2.1.2 Isoeffect calculations
Calculating the “effect” E from a fractionated treatment is typically done using the neg-
ative logarithm of Eq. (2.2)
E=αD+βdD=D(α+βd), (2.3)
α/β=3 Gy
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9which can be generalized to n fractions of arbitrary dose di 
n
E=�  αdi+βdi2   . (2.4)
i=1
Furthermore, to get a clinically familiar reference from conventional fractionation for 
this “effect”, it is converted into what usually is denoted the equivalent dose in 2-Gy 
fractions (EQD2) or the biological equivalent dose (BED). This thesis will however follow 
the upcoming recommendation of the International Commission of Radiation Units 
and Measurements (ICRU) and use the terminology equieffective dose† [42]. If a treat-
ment regimen is compared to another one delivered with X Gy per fraction, the equi-
effective dose is denoted EQDXα/β where the subscript refers to the α/β value that the dose 
is equieffective to. The EQDXα/β for several fractions is calculated
EQDXα/β(α+βX)=D(α+βd) (2.5) 
or, in the general case,
�di(di+α/β)
EQDXα/β=D
(d+α/β) = i    . (2.6)
(X+α/β) (X+α/β)
The EQD2 and BED become special cases of EQDXα/β denoted EQD2α/β and EQD0α/β, respec-
tively. The role of α/β as a measure of the fractionation sensitivity is evident: a low (high) 
α/β value, results in large (small) changes in EQDXα/β.
Extensions to the LQ model to include the incomplete repair between fractions, the 
dose-rate effect, and corrections for OTT have been suggested [12]. Neither of these 
extensions were considered necessary for the included papers and will therefore not be 
further discussed in this thesis.
2.1.3 The linear-quadratic model for normal tissue
The LQ model was introduced as a means to describe the SF of tumour cells after irradi-
ation, but it is widely applied to normal tissues as well [41]. While its biological interpre-
tation is straightforward for tumours, where we aim to eradicate tumour cells, it is less 
clear what the target cells for normal tissue may be. The concept of functional subunits 
(FSUs) has been proposed together with the concepts of serial and parallel tissue organ-
ization [29]. But for a specific organ it is not clear which structure within the organ 
this FSU corresponds to. Although a radiobiological interpretation of the LQ model for 
normal tissue may be beneficial or interesting, it is not necessary for NTCP modelling. 
For this purpose, it is enough to recognize that it is a model that provides fits in good 
correspondence with observed data. However, extrapolating models to situations very 
† The notations in Papers I and III and in this framework will therefore not be consistent.
10
different from the ones where they were established should always be done with caution.
Generally speaking, tumours have higher α/β values than normal tissue. Consequently, 
fractionated irradiation with small doses per fraction usually allows for a higher 
tumour dose and spares the surrounding tissues. On the other hand, if the tumour α/β 
value is equal to or lower than that of normal tissue, larger doses per fraction may be 
safely delivered. In cases where we do not know the actual values, generic values of 10 
Gy and of 3 Gy are typically used for tumour and normal tissue, respectively [42].
2.1.4 Fractionation effects at (very) high doses per fraction
Several models have been suggested to take the effect at higher dose per fraction into 
account [13, 14, 16], among those is the linear-quadratic-linear (LQ-L) model suggested 
by Astrahan et al. [14]. In their model, the fractionation effect is described by the LQ 
model up to a dose per fraction dt, and it then becomes linear for doses higher than dt 
continuing with the same slope as at dt. The LQ and the LQ-L models are illustrated in 
Figure 2.2.
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Figure 2.2. The LQ model and the LQ-L model for α/β=3 Gy and two different dt.
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2.2 Late toxicity following radiation therapy
Normal tissue toxicity is caused by incidental irradiation of tissue surrounding the 
tumour. Toxicity manifesting more than three months after completed radiation ther-
apy is classified as late toxicity. Whether a patient experience a toxicity, or side effect, 
can be detected in different ways: it can be reported by a healthcare professional during 
follow-up, or by the patient herself or himself [41]. Specific separate efforts, prospec-
tively or retrospectively, may also be undertaken to systematically evaluate the presence 
of such damage. One such example is questionnaire-collected data.
In NTCP modelling, we aim to quantify the relationship between the delivered dose in 
an OAR and a specific toxicity - an atomized symptom - that is “likely to reflect specific 
radiation pathophysiologies” originating from the OAR in question [19, 43]. The studied 
side effect should be systematically evaluated meaning that the sensitivity and specific-
ity for its detection should ideally be the same for all subjects. Several grading systems 
such as the Common Terminology Criteria for Adverse Events (CTCAE, [44]), the Radi-
ation Therapy Oncology Group in North America and the European Organization for 
Research and Treatment of Cancer (RTOG/EORTC, [45]), and Late Effects Normal Tissue 
Subjective Objective Management Analytical (LENT-SOMA, [46]) have been developed to 
allow for structured and consistent classification of late toxicity. Both CTCAE and RTOG/
EORTC can combine different late toxicities into one grade. The LENT-SOMA system 
clearly separates different aspects of toxicity associated with the same OAR and also how 
these are scored.
A toxicity reflecting a specific underlying pathophysiology in an OAR can be measured 
in different ways. For instance, pain may either be assessed as ‘how much’ or ‘how often’. 
Regardless if the toxicity is measured on a continuous, discrete, or categorical scale, a 
criterion, a cut-off, has to be set to define the complication; a task that may be diffi-
cult in itself  [19]. According to this criterion, subjects will be dichotomized into either 
having or not having the studied side effect. Some toxicities, such as rib fracture, are 
naturally binary, while others, such as amount of pain, are not. The combination of tox-
icity and decided cut-off is denoted endpoint.
The studied endpoint in Paper I was radiation-induced rib fracture as verified by CT 
scan; this endpoint is binary and was scored as 1 in case of fracture and 0 if there was no 
fracture. In Papers II, III, and V, a wide spectrum of genitourinary toxicities after pros-
tate cancer radiation therapy was studied. These data were taken from a postal-based 
questionnaire. None of these symptoms were binary and for each studied symptom  
cut-offs had to determined. The development of the questionnaire is described below.
2.2.1 Questionnaire development and principles
David Alsadius et al. developed a study-specific questionnaire according to the princi-
ples at The Divisions of Clinical Cancer Epidemiology at the Sahlgrenska Academy and 
the Karolinska Institute to assess the occurrence of late toxicity after prostate cancer 
radiation therapy [47-50]. They began with a structural assessment of previous ques-
tionnaires from the divisions concerning symptoms after pelvic irradiation or prosta-
tectomy. They classified the questions in these questionnaires according to the symp-
tom they measured (e.g. urinary leakage) to conceptualize clear-cut definitions of each 
symptom. These definitions were then operationalized into questions in the new ques-
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tionnaire. To make sure that no common symptom was missing, they interviewed four 
prostate cancer survivors. They validated the questionnaire using 15 men (10 prostate 
cancer survivors) to make sure that the questions were not misinterpreted and directly 
understood. The questionnaire also contained questions on demographics and comor-
bidities.
Toxicity data collected like this are well suited for NTCP modelling. When we evaluate a 
symptom which may be caused by other factors besides ionizing radiation, the informa-
tion from a control population may assist in determining each factors relative contribu-
tion to the studied symptom [47].
2.3 NTCP modelling
2.3.1 Dose distributions
2.3.1.1 DOsE-VOlumE HisTOgRAms
A dose-volume histogram (DVH) is a summary of a 3D dose distribution where the spa-
tial dose information is discarded to provide a condensed and understandable descrip-
tion. It will therefore not be possible to recreate the 3D dose distribution from a DVH 
since the spatial dose distribution is lost. In the clinical workflow, OAR DVHs are used 
for treatment plan comparison and to create dose distributions for inverse treatment 
planning. In NTCP modelling, the DVH is the most commonly used description of the 
OAR dose distribution to relate the delivered OAR dose to the studied toxicity. 
The two most common DVH representations are the cumulative DVH and the differen-
tial DVH; if one representation is known, the other can be calculated. For treatment plan 
comparison, cumulative DVHs are most commonly used. The relationship between dose 
distribution and different DVH representations is shown below (Figure 2.3). The volume 
represention of a DVH is either on absolute or relative form.
A DVH can be exported as a text file from the TPS where the dose bin size is user selecta-
ble. All DVHs used for the analyses in this thesis used a dose bin size, denoted ΔD, of 0.5 
Gy.  An important property of the differential DVH is that the area under the curve is 
the volume of the OAR.
V= � vi ΔD
 i 
(2.8)
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Figure 2.3. Relationship between dose distribution, DVHs and their tabular representation.  
Left: dose distribution; absorbed dose in each 1 cm3 volume .  
Top: corresponding cumulative DVH with dose bin size of 5 Gy. 
Bottom: corresponding differential DVH with dose bin size of 5 Gy. .
Since the spatial dose distribution is lost, a DVH representation may have some draw-
backs. If one part of the OAR is more important for organ functionality than another or 
if the radiation sensitivity varies over the volume, some relevant information may be 
lost. For oblong organs (spinal cord, rectum etc.) high doses across the OAR may cause 
more damage than the same dose along it.
2.3.1.2 DOsE-DisTRiBuTiOn DEscRipTORs
The dose distribution in an OAR is often inhomogeneous. There are several ways to 
summarize a dose distribution or the DVH into one representative value, a descriptor 
value. The mean dose is a common measure of the total dose in a volume. It is routinely 
reported by the TPS and it can also be calculated from any of the DVH representations.
The cut-off volume (DV) and cut-off dose (VD) descriptors are other common ways 
to summarize a DVH into one value [27]. Despite their names, cut-off dose defines a 
volume and vice versa. VD denotes the volume receiving at least dose D, and DV denotes 
the minimum dose in the volume v receiving the highest dose. Their relationships to a 
cumulative DVH are shown in Figure 2.4. Since a cumulative DVH use either relative or 
absolute volume, these dose descriptors do so too.
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Figure 2.4. Visual depiction of cut-off volume and cut-off dose. The cumulative DVH can be on either 
absolute or relative volume form and this will affect the cut-off parameters accordingly.
The simplest description of the maximum dose is by the highest voxel dose. However, 
this maximum dose may not be placed at the same OAR location for each fraction, and 
considering that the volume of each voxel typically is a few mm3, this measure may not 
be biologically relevant. The ICRU denotes the near-maximum dose as the D2% [51]. In an 
analogues definition, the ICRU report no. 58 recommend that D2cm3 should be reported 
for interstitial BT [52]. Both D2% and D2cm3 are considered in Papers IV and V. The D2cm3 
has the advantage that the entire OAR may not need to be contoured or encompassed 
by the field-of-view during image acquisition. The difference between maximum dose 
and near-maximum dose can be large for dose distributions delivered with steep dose 
gradients. 
Cut-off descriptors have been used in NTCP modelling [27]. However, they only consider 
a limited aspect of the DVH; two DVHs with very different shapes may still have some 
DV and VD in common. Different ways to take the entire shape of the DVH into account 
have been proposed [53-55]. One example is Deff which is calculated for a differential 
DVH as
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where n is the volume effect parameter [21, 22, 54]. When n=1 the result is the mean dose 
and when n→0 Deff becomes the maximum dose. When Deff is used together with the 
probit dose-response curve, Eq. (2.12a), it is called the LKB model. The Deff is equivalent 
to the (later suggested) generalized equivalent uniform dose (gEUD), where the parame-
ter a=1/n is used instead [55].
2.3.2 Overview of dose-response curves
The relationship between dose and the risk of a given toxicity is usually modelled by an 
s-shaped function – also referred to as a dose-response or an NTCP curve. The curve is 
usually characterized by its position (D50) and steepness (γ50) (Fig 2.5) [56-58]. D50 is the 
dose required for a 50% risk of complication and γ50 is the normalised dose-response 
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gradient or the steepness (Figure 2.5). γx is generally defined as
γx=DxNTCP’(Dx) (2.10)
for an arbitrary response level x. γ50 has the suitable interpretation that an increase in 
1% at D50, increases the NTCP by γ50 percentage points. There are many mathematical 
options to describe dose-response curves, but regardless of which specific formula is 
used, the curves are in many cases completely described by D50 and γ50.
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Figure 2.5. Position (D50) and slope at D50 of a dose-response curve. The relation between the slope and 
the steepness is given by Eq. (2.10).
Various expressions such as the logistic function (Eq. 2.11), the cumulative normal dis-
tribution (probit function) (Eq. 2.12a), and the log-logistic function (Eq. 2.13) are used 
[57]. The actual difference between them is very small (Figure 2.6) and which function 
to use in NTCP modelling is not critical. It can be noted that although some toxicity is 
so severe that we would not allow its risk be anywhere close to 50%, D50 and γ50 are still 
useful to describe the position and the steepness of the dose-response curve.
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Figure 2.6. Logistic, probit and log-logistic dose-response curves.
2.3.3 Consideration of fractionation effects in NTCP modelling
As stated in the beginning of this chapter, calculating the NTCP typically involves two 
steps: first, calculating one value that will represent the entire dose distribution, and 
second, using this value as input in a dose-response curve. Consequently, the fractiona-
tion effect in NTCP modelling can be considered either in the first or in the second step; 
how this can be done is outlined in sections 2.3.3.1 and 2.3.3.2, respectively. It should also 
be noted that fractionation effects will be more or less present in all‡ inhomogeneous 
OAR dose distributions meaning that one at least needs to consider how fractionation 
effects will impact NTCP modelling. Some typical situations are described below:
 ◆ A fractionation correction needs to be considered when the repre-
sentative value (for instance Deff) takes the entire shape of DVH into 
account. This means that the fractionation correction occurs in the 
first step. An α/β value has to be selected; this may influence the 
modelling results.
 ◆ A fractionation correction needs to be considered when the treat-
ment fraction size varies between fractions. This also means that the 
correction is done in the first step and that an α/β has to be selected; 
this may influence the modelling results.
 ◆ When a homogeneous dose is delivered with a fixed dose per fraction 
for all patients, but in a varying number of fractions, the fractiona-
tion effect is constant and will not affect the modelling results.
 ◆ If the dose is delivered with a fixed number of fractions for all 
patients, but with varying dose there will be different doses per frac-
tion between patients. A dose-response curve adapted to this situa-
tion was derived in Paper I. α/β is explicitly included in that expres-
sion, but  as shown below in section 2.3.3.2,  the selected value will not 
affect the modelling results.
‡ The exception is a treatment that partially irradiates an OAR with a homogeneous dose while the rest of 
the OAR receives zero dose.
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There is also the situation where the purpose of modelling is to estimate the fraction-
ation sensitivity. This was briefly evaluated in Paper III for urethral pain and was also 
recently reported by Borst et al. for radiation pneumonitis following hypofractionated 
SBRT [59].
2.3.3.1 FRAcTiOnATiOn-cORREcTED DOsE DisTRiBuTiOns AnD DVHs
This section describes representative values can be calculated from the dose distribution 
or the DVH with consideration of the fractionation effect. The most general approach is 
to perform the fractionation correction on the voxel doses in the 3D dose distribution 
before exporting the DVH. This is however dependent on functionality of the treatment 
planning system (TPS) or on independently developed software using data exported 
from the TPS and may consequently not always be possible.
When the entire treatment is delivered with the same OAR dose distribution, there is a 
more convenient way to take the fractionation effect into account. In this case, the frac-
tionation correction can easily be performed directly on the dose column of a (cumula-
tive or differential) DVH (see Figure 2.3). The effect is shown in Figure 2.7.
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Figure 2.7. Cumulative DVH without and with fractionation correction assuming α/β=3 Gy and 23 fractions.
Any of the dose-distribution descriptors from the 2.3.1.2 can then be calculated in frac-
tionated-corrected versions. Specifically, the fractionation-corrected effective dose, 
EQDeff Xα/β is calculated as
EQDeff Xα/β=� 
ΔD
V � vi �
Di(di+α/β)
�(X+ α/β)
1/n
�
n
i
 .                                                                                          (2.14)
Correcting for fractionation effects can be more challenging if the treatment is deliv-
ered with different dose distributions, as for instance in multiple-phased or multi- 
modality treatments [60]. Even if we can create a treatment plan sum in the TPS, this is 
usually the sum of the absorbed dose distributions i.e. the fractionation effect is ignored. 
The general solution is to apply the fractionation correction for the contributing 3D dose 
EQD23 or absorbed dose [Gy]
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distributions before they are added. This depends, as mentioned above, on the function-
ality of the TPS. Exporting and using one DVH for each contributing dose distribution 
does not work in the general case since the spatial dose information is lost when the 
DVH is calculated and the risk is to add doses from different voxels.
2.3.3.2 FRAcTiOnATiOn-cORREcTED DOsE-REspOnsE cuRVEs
This section describes how dose-response curves can be used to take the fractionation 
effect into account. Again α/β from the LQ model is used to describe the fractionation 
sensitivity, but the following can be adapted to any model.
In Paper I, we stated that there are two different types of dose-response curves. This was 
however not entirely true as there actually are three types.
 ◆ In the first case we have the same fractionation effect for all patients. 
The same dose d per fraction is delivered in a different number of 
fractions for different patients. 
 
 
(2.15)
 
 
The fractionation sensitivity is implicitly included in this expression 
since the value of D50 is dependent on the dose per fraction d. A sub-
script d is added to define a γ50,d that denotes the steepness for a situa-
tion where the dose per fraction is constant. It can be shown that γ50,d 
is independent of the dose per fraction d [57, 58]. 
 ◆ In the second case there is a different dose per fraction between 
patients, but the same number of fractions is delivered for all 
patients, that is, we have different fractionation effects between 
patients. This dose-response curve is derived in Paper I using the LQ 
model. 
 
 
(2.16)
 
 
The fractionation sensitivity is explicitly included in this expression. 
A subscript n is added to define a γ50,n that denotes the steepness for 
a situation where the number of fractions is constant. α/β has to be 
included, but it can be shown that its value will be less important (see 
later in this section). This expression is applied to radiation-induced 
rib fractures in Paper I. 
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 ◆ The third case is the general situation. Now both the dose per frac-
tion and the number of fractions are allowed to vary.  
 
 
(2.17)
 
In this case we must also explicitly take the fractionation sensitiv-
ity into account, but this is done prior to using this expression. The 
steepness for this curve is the same as in Eq. (2.15).
From the expression for the equieffective dose in Eq. (2.6) it becomes clear that Eq. (2.15 
and 2.16) are special cases of the general expression in Eq. (2.17). Furthermore, the rela-
tionship between the steepness for a treatment delivered with fixed dose per fraction 
(γ50,d) and one delivered with a fixed number of fractions (γ50,n) was also derived in 
Paper I; a result previously obtained by Bentzen [56]:
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Both γ50,d and γ50,n can be used in Eq. (2.16), but to keep the interpretation of the normal-
ized dose-response gradients they must be used in the right context. Using Eq. (2.15) and 
Eq. (2.16), will give the same result if the α/β value or n are very large; in this case γ50,d 
and γ50,n will be equal as well.
A dose-response curve for a fixed dose per fractions is less steep than a dose-response 
curve for a fixed number of fractions, Figure 2.8. In the latter case, when the total dose 
is increased (decreased), the dose per fraction is increased (decreased) as well.
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Figure 2.8. Dose-response curves for a fixed dose per fraction (dotted curve) and a fixed number of frac-
tions (solid curve).
We initially thought that if the dose-response curve for a treatment delivered with a 
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fixed number of fractions could be accurately described using Eq. (2.16), we would be 
able to estimate the value of α/β. Dose-response curves plotted for different values of 
α/β, however, showed very little separation (Figure 2.9).
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Figure 2.9. Dose-response curves for a three-fraction treatment using different values of α/β; D50=50 Gy 
and γ50,n=2.0 for all curves.
The potential consequences for NTCP model parameter estimation in this situation can 
be quantified using a simulated dataset (see section 2.4 for statistical methods). Assume 
that the correct model has the parameters D50=50 Gy, γ50,n=2.0, and α/β=3.0 Gy and that 
the treatment is delivered in three fractions. For this ‘treatment’ we have observed 11.2 % 
risk of complication at 35.0 Gy, 50.0% at 50.0 Gy and 85.2% at 60.0 Gy using 200 patients 
at each dose level. The value of the log-likelihood function, Eq. (2.21), is directly propor-
tional to the size of the dataset, that is, the size of the simulated dataset does not impact 
the estimation of the best fitting parameters. Parameter estimation for Eq. (2.16) was 
done using values of α/β from 0 to 10 Gy, in steps of 1 Gy, and for an infinite α/β value. 
After substituting Eq. (2.18) into Eq. (2.16), γ50,d, was also estimated from these data. Fur-
thermore, parameters for Eq. (2.15) were estimated as well.
The maximum value of the log-likelihood function revealed that D50, γ50,n as well as γ50,d 
showed little dependence of α/β values from 0 to 10 Gy (Figure 2.10, panels A-D). The 
estimated γ50,d in panel D was related to the estimated γ50,n in panel C exactly as pre-
dicted by Eq. (2.18). Parameter estimation using Eq. (2.15) resulted in a somewhat lower 
D50, but the maximum value of the log-likelihood function was not notably differ-
ent even under these highly ideal conditions. The estimated steepness using Eq. (2.15), 
γ50,d=1.88, was however much larger compared to the otherwise estimated γ50,d in panel 
D. The resulting dose-response curves and the underlying simulated dataset are shown 
in Figure 2.11.
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Figure 2.10. Analyses of the impact of different α/β values on estimated parameters using Eq. (2.16) for 
the simulated 600 subjects.  
A: Profile log-likelihood (pll) values; pLL for grey dot is estimated using an infinite α/β value.   
B: Estimated D50;  D50 for grey dot is estimated using an infinite α/β value. 
C: Estimated γ50,n; γ50,n  for grey dot is estimated using an infinite α/β value. 
D: Estimated γ50,d; γ50,d for grey dot is estimated using Eq. (2.15).
 
0
25
50
75
100
0 10 20 30 40 50 60 70
Figure 2.11. Estimated dose-response curves for α/β=1 Gy, α/β=3 Gy, α/β=10 Gy, and for Eq. (2.15).  The 
vertical error bars show the 95% CI for the simulated 200 subjects per dose level.
A few conclusions can be drawn from this. Robust estimations of D50 and γ50,n are feasi-
ble even though we do not know the α/β value. Ignoring fractionation effects and esti-
mating parameters using Eq. (2.15) will result in equally good model fits and reasonably 
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similar D50, but the estimated steepness is somewhat different.
Even though using Eq. (2.15) resulted in an equally good model fit in this simulated 
dataset, there will be consequences when adapting the dose-response curve to other 
fractionation regimens. For instance, correctly calculating the dose-response curve 
parameters to the equieffective dose in 10-Gy factions, EQD103, will give a D50 and a 
steepness of 75.6 Gy and 1.08, respectively. However, first using Eq. (2.15) for parameter 
estimation and then not realizing that the steepness depends on the treatment situation 
will result in an incorrect dose-response curve (Figure 2.12). If we accept a maximum 
risk of 10% for this complication, we will set our dose limit at EQD103=52 Gy with the 
incorrect steepness, but the risk at this dose is actually 20% with the correct steepness.
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Figure 2.12. Dose-response curves for equieffective dose in 10-Gy fractions, EQD103, using either the cor-
rect steepness (solid curve) or the incorrect steepness (dashed curve).
The steepness of a dose-response curve for a fixed number of fractions partly origi-
nates from the fractionation effect and partly from the inherent steepness. Using Eq. 
(2.15) instead of Eq. (2.16) for parameter estimation when the treatment is delivered 
with a fixed number of fractions means that the fractionation effect is ignored and this 
will lead to an overestimation of the inherent steepness. To utilize an estimated dose- 
response curve in other fractionation regimens, the γ50 as well as the D50 must be recal-
culated using Eq. (2.18) and Eq. (2.6), respectively.
2.3.4 Incorporation of non-treatment-related factors in NTCP modelling
There are circumstances in where the NTCP is needs to be modelled using a dose-re-
sponse curve with a restricted risk range. This may be the case when the studied end-
point is present among non-treated subjects or when the risk of the endpoint cannot be 
larger than a certain value. In the general case, this can be described by the following 
equation (exemplified by using the logistic dose-response curve with absorbed dose)
 
. (2.19)
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Here B denotes the risk for subjects that experience a toxicity for other reasons than 
irradiation and T denotes the maximum attainable risk. B may reflect the occurrence 
rate of a studied toxicity in a non-irradiated control population (background rate). 
Since B can be larger than 50%, the usual definition of D50 is inappropriate and D50 in 
Eq. (2.19) is interpreted as the dose required to increase the risk by half the distance 
between B and T and the γ50 is the steepness at that dose (see Figure 2.13). There are 
other methods to include clinical factors in NTCP modelling such as those described by 
Tucker et al. and El Naqa et al. but those were not explored in this thesis [61, 62].
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Figure 2.13. A dose-response curve that is restricted to values between B and T.
2.4 Statistical methods
2.4.1 Maximum likelihood estimation
Maximum likelihood estimation (MLE) is a commonly used method to estimate NTCP 
model parameters from a dataset with known dose distributions and binary endpoints 
(0 for no toxicity and 1 for toxicity). This is done by calculating the logarithm of the  
likelihood function, the log-likelihood (LL) function, according to [63]
 
(2.20)
where pk represents the k NTCP model parameters to be estimated; Di and Dj are the 
known doses for N subjects with toxicity and M subjects without toxicity, respectively. 
The combination of parameters pk that maximizes the value of the LL function is the 
parameter value combination that best describes the observed outcome for the dataset 
in question. The maximum value of the LL function is denoted ML and the correspond-
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ing estimated parameters the maximum likelihood estimates. 
Obtaining the ML by numerical optimization techniques cannot be guaranteed since 
the optimization procedure may converge to a local maximum of the LL function 
instead of finding the global maximum. This can be avoided by calculating the entire 
LL landscape, that is, calculating the LL function for a large number of combinations of 
pk. The ML and corresponding maximum likelihood estimates can then easily be found. 
One need to make sure that the relevant range for each parameter is included in the cal-
culation and that the resolution of the parameters is sufficiently high. This brute force 
method may be time-consuming, especially if the number of model parameters is large, 
but it has the advantage that the LL landscape only needs to be calculated once and the 
result can be saved for analyses at a later time.
2.4.2 Parameter confidence intervals and NTCP uncertainty
One-dimensional confidence intervals (CI) for the maximum likelihood estimates 
were calculated using the profile log-likelihood method [63]. The profile LL function for 
parameter p1 among the k parameters to be estimated is given by
pLL(p1)=max(LL(p2-k|Di , j ,p1)) (2.21)
where p2-k are the remaining k-1 model parameters. The CI at the significance level α for 
p1 is then obtained by finding all parameter values where 
ML−pLL(p1)≤0.5χ2(1−α,1) (2.22)
is fulfilled. The χ2(1-α, 1) denotes the chi-square distribution with one degree of freedom 
for the chosen significance level α [63]. In practice both the 68% and 95% CI are calcu-
lated; these correspond to 0.5χ2 values of 0.49 and 1.92, respectively. When the entire 
LL landscape has been calculated, the profile log-likelihood CIs are easily obtained by 
selecting the appropriate parameter range according to Eq. (2.22).
The uncertainty in parameter estimates will impact the estimated NTCP. This has been 
extensively analysed by Schilstra et al. [64]. Another less computationally intensive 
approach was suggested by Gagliardi et al. [65]. Assume that the ML has been estimated 
for the dose-response curve parameters D50 and γ50, and that the entire LL landscape has 
been calculated as well. The confidence region at the significance level α of D50 and γ50 is 
defined as the region for which all (D50, γ50) combinations satisfy
ML−LL(D50 ,γ50)≤0.5χ2(1−α,2). (2.23)
To calculate the NTCP CI for one dose level of the dose-response curve, NTCP values are 
calculated for all parameter combinations within the confidence region. The CI at this 
dose level is now defined by the range between the minimum NTCP value and maxi-
mum NTCP value.
2.4.3 Model comparison
For comparison of different models fitted to the same dataset, the Akaike Information 
Criterion (AIC) can be used [63].
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AIC=−2×ML+2×k. (2.24)
Here ML and k once again denotes the maximum value of the LL function and the 
number of parameters, respectively. Comparing models, the smaller the AIC, the better 
the model. The AIC provides a measure to avoid overfitting, i.e. to include parameters 
that do not substantially improve the fit.
2.4.4 Receiver-operating characteristics
Maximum likelihood estimation will find the best fitting NTCP model parameters and 
the AIC will indicate the better model among a set of competing models. It will, however, 
not reveal if the best model can assist in discriminating those with toxicity from those 
without toxicity. ROC investigates how a binary classifier discriminates responders from 
non-responders by setting a decision level (Figure 2.14) [66-68]. The sensitivity is the 
proportion of responders that were correctly categorized according to the decision level. 
The specificity is the corresponding proportion of non-responders that were correctly 
categorized.
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Figure 2.14. Principle of obtaining an ROC curve by calculating the sensitivity and the specificity at each 
position of the decision level.
By letting the decision level span the entire range of doses and calculate the sensitivity 
and specificity at each level, an ROC curve is traced (Figure 2.15).
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Figure 2.15. The ROC curve obtained from Figure 2.14.
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The area under the curve (AUC) will then reveal the model’s ability to discriminate 
responders from non-responders.  In Figure 2.14, the horizontal axis is dose, but 
could have been the calculated NTCP; ROC evaluates the order in which responders 
and non-responders will appear. For a poor model, the order between responders and 
non-responders is random and the AUC will be the 0.5, i.e. no better than flipping a coin. 
If the AUC is 1, the model has created a perfect separation; this is however unattainable 
in radiation therapy since there always will be a dose range occupied by both respond-
ers and non-responders.
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3. HYPOFRACTIONATED 
RADIATION THERAPY 
AND LATE TOXICITY
3.1 Non-small-cell lung cancer – rib fractures (Paper I)
During routine follow-up of lung cancer patients treated with hypofractionated radiation therapy at the Sahlgrenska University Hospital, a few cases of radia-
tion-induced rib fractures were found after patients reported pain originating from the 
treated area. This initiated a systematic investigation among all patients and subse-
quently an NTCP modelling effort to analyse the risk of radiation-induced rib fracture. 
Mathematical expressions for dose-response curves taking the fractionation effect into 
account were also derived.
3.1.1 Non-small-cell lung cancer
Lung cancer is a common form of cancer in Sweden with about 3600 new cases each 
year [69]. It is the overall leading cause of cancer-related deaths among Swedes; 3500 
died of the disease in 2010 [70]. There are two major types of lung cancer: small-cell 
lung carcinoma and non-small-cell lung carcinoma (NSCLC); in this thesis only patients 
with NSCLC are investigated.
The major cause of NSCLC is a history of smoking which represents about 85% of cases 
[71]. The extent of the disease at diagnosis determines treatment options and is a strong 
predictor of expected outcome [72]. This makes correct staging essential. For stage 1 
NSCLC – localized tumour with no lymph node involvement - surgery, with or without 
adjuvant chemotherapy, is currently the primary treatment option with curative intent. 
However, some patients are medically inoperable due to comorbidity and a few refuse 
surgery. Hence, radiation therapy, with or without chemotherapy, has been the alterna-
tive therapeutic modality for these patients.
3.1.2 Radiation therapy
Using conventionally fractionated radiation therapy to total doses of 60-70 Gy for stage 
1 NSCLC has generally resulted in poor tumour control with a typical local recurrence 
rate of 40% [73]. In the attempts to achieve better local control and survival, the pre-
scribed doses have been increased over the years [74-76]. This became possible with the 
introduction of 3D conformal radiation therapy (CRT) keeping the volume of irradiated 
healthy lung low and keeping the often dose-limiting radiation-induced pneumonitis 
at a tolerable level. However, using conventional fractionation, the increased prescribed 
dose was counteracted by the increased OTT that negatively impacted tumour con-
trol  [74, 76, 77]. SBRT was developed at the Karolinska University Hospital, Stockholm, 
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Sweden in the early 1990’s for patients with liver tumours or lung metastases [34, 36]. In 
order to improve the poor outcome of conventional treatments and encouraged by the 
positive results from intracranial stereotactic treatments, they argued that
[t]he proposed method can be expected to give favourable results for 
tumours in large organs with a high tolerance to partial volume irradia-
tion. Thus, liver and lung are organs that could be expected to be suitable 
for treatment of relatively large targets with this method. [36]
To decrease the risk of treatment-related toxicity in OARs with high tolerance to partial 
volume irradiation, the irradiated volume outside the tumour must be kept small. This 
was primarily accomplished by a dedicated patient set-up device – a stereotactic body 
frame – that had been developed to be used together with a standard linear accelerator. 
The body frame enabled an accurate patient positioning relative to the linear accelerator. 
The body frame also included an optional diaphragm press to control tumour motion 
due to breathing. This set-up made it possible to have small clinical target volume (CTV) 
margins keeping the irradiated volume of normal tissue small. To further decrease the 
dose outside the planning target volume (PTV), they employed a treatment planning 
strategy where the dose was prescribed to the periphery of the CTV and the central part 
of the tumour received considerably more than 100% [36]. The first patients were treated 
with 1-3 fractions.
3.1.3 Stereotactic body radiation therapy at the Sahlgrenska University 
Hospital
The principles developed at the Karolinska University Hospital were adopted at the 
Sahlgrenska University Hospital for medically inoperable  NSCLC patients and the first 
patient was treated using the stereotactic body frame (Elekta AB, Sweden; Figure 3.1) in 
September 1998. Encouraging treatment results for the first 45 patients were reported 
in 2005: 39 months median overall survival and little toxicity [78]. The treatment at the 
Sahlgrenska University Hospital was (and is still) prescribed to 45 Gy in three fractions 
and is to be delivered in less than one week. The prescribed dose is the minimum dose 
at the periphery of the PTV.
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Figure 3.1. Patient in the stereotactic body frame at the Sahlgrenska University Hospital.  
The patient is immobilized using a vacuum pillow and the body frame is placed relative to 
the treatment machine using designated rulers.
The patient is positioned in the body frame and a pre-treatment CT scan is performed. 
The gross tumor volume (GTV) is then contoured on each axial slice in the TPS and 
the CTV is defined as the same volume as the GTV. To create a PTV, margins of 5 mm in 
the transversal plane and 10 mm in the cranio-caudal direction are added to the CTV. 
The treatment is delivered with 4–6 coplanar or non-coplanar 4-6 MV photon beams 
shaped with an MLC. This results in an inhomogeneous PTV dose distribution with cen-
tral doses of 63-69 Gy as well as very steep dose gradients outside the PTV keeping the 
high-dose region small and the mean lung dose low (Figure 3.2, top). CT imaging was 
repeated before each fraction to verify the position of the tumour relative to the coordi-
nate system of the body frame.
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Figure 3.2. Top: Dose distribution in a transversal pre-treatment CT slice for an NSCLC SBRT patient.  
Bottom: Dose distribution superimposed on a follow-up CT.
3.1.4 NTCP modelling of radiation-induced rib fracture (Paper I)
All patients treated with SBRT were monitored after treatment with regards to both tox-
icity and tumour control. The follow-up included CT scans performed every 6 months. 
The endpoint for this work was radiation-induced rib fracture as verified by CT scan 
at any time after treatment (Figure 3.2, top). It should be pointed out the endpoint was 
PTV
CTV
Fracture
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defined for each rib and some patients did experience multiple fractures (Table 1 in 
Paper I). In total, 13 rib fractures in seven patients were found close to the treatment 
volume and for which dose distribution data were available. All ribs receiving at least 
3×7.0 Gy were separately contoured in the TPS. This resulted in 81 contoured ribs, 13 with 
and 68 without fracture, and the DVH for each rib was exported for analysis. Further-
more, CT scans for the patients containing the 13 fractured ribs were exported to the 
TPS and co-registered with the pre-treatment CT scans. This way we could determine 
which rib DVH that corresponded to which rib from the follow-up CT and assign the 
correct endpoint (0 for no rib fracture and 1 for rib fracture). The entire dataset is shown 
in Figure 3.3. Although the dose gradient outside the PTV is steep, some ribs are located 
within the PTV (Figure 3.2, bottom) and the maximum doses for those ribs are conse-
quently higher than the prescribed dose of 45 Gy (Figure 3.3).
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Figure 3.3. DVHs for ribs without (thin curves, n=68) and with rib fracture (thick curves, n=13) for 26 
patients treated with SBRT.
Five different ways of summarizing each DVH into one descriptor value were used: cut-
off volumes (DaV and DrV), cutoff doses (aVD and rVD), and the mean absorbed dose 
(see section 2.3.1.2 for definitions). Each descriptor was then used as input in dose- or 
volume-response curves to find the NTCP model that best described the risk of radia-
tion-induced rib fracture.
The strongest association between dose and risk of rib fracture lay in the high-dose/ 
small-volume region of the DVH. Both absolute and relative DVHs were assessed, but 
models for absolute volume provided better fits. The dose-response curve for D2cm3 was 
described by D50=49.8 Gy and γ50,n=2.05 (Figure 3.4). This results in 10% risk of radia-
tion-induced rib fracture for a total dose of 34 Gy when the treatment is delivered in 
three fractions. Using ROC analysis, the AUC was 0.82±0.07 (1 SEM), indicating a high 
predictive strength when using D2cm3 as a dose descriptor in the model.
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Figure 3.4. Dose-response curve for the relationship between the dose to D2cm3 and rib fracture (solid 
curve) and the corresponding 68% CIs (dashed curves). The descriptor values have been binned into five 
groups to illustrate the observed rib fracture. The horizontal bars show mean±1 SD and the vertical error 
bars show 68% CI for the observed probability. 
3.2 Prostate cancer - genitourinary 
toxicity (Papers II-V)
In 2008, a questionnaire surveying radiation-induced toxicity was sent out to all pros-
tate cancers survivors treated with radiation therapy at the Sahlgrenska University 
Hospital during 1993 to 2006. The survivors had been treated with either primary EBRT, 
salvage EBRT following prostatectomy, or a combination of EBRT and HDR BT. A group 
of non-pelvic-irradiated men were also included in this study to provide information 
about symptom occurrence in population-based individuals (background rate). For 
each survivor, ten OARs were delineated on the EBRT pre-treatment CT, the dose dis-
tribution was reconstructed from treatment records and DVHs were exported. The BT 
OAR dose contribution could not be assessed from treatment documentation; this was 
addressed in Paper IV.
The questionnaire contained, among other things, 21 questions on genitourinary symp-
toms. The overall purpose of Papers II-V was to use the obtained dose distribution data 
for NTPC modelling of genitourinary toxicity data from this questionnaire. In Paper II, 
an overview of symptoms among survivors and controls was presented. NTCP model-
ling was performed for urethral pain and incontinence in Paper III and V, respectively. 
Of specific interest was to investigate how the large dose per fraction delivered with BT 
– 10 or 15 Gy – affected the outcome compared to men treated with conventionally frac-
tionated EBRT.
3.2.1 Prostate cancer
Prostate cancer is the most common form of cancer among Swedish men with about 
9700 men diagnosed each year [69]. Prostate cancer is also the leading cause of cancer-
related death among Swedish men, with about 2400 yearly deaths [70]. The disease 
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becomes more common with age: in 2010 about half of newly diagnosed men were 70 
years or older [69]. Various examinations such as serum markers of prostate- specific 
antigen (PSA), histological grade (Gleason score), and evaluation of disseminated 
disease are used to assist in choice of treatment strategy. If the disease is confined to 
the prostate, the major primary treatment options are surgery and radiation therapy 
modalities such as EBRT and BT.
3.2.2 Radiation therapy
Conventionally fractionated EBRT to a total dose of 60-70 Gy using non-conformal box 
techniques was initially used in the treatment of prostate cancer. This resulted in mod-
erate tumour control, but high risks for urinary bladder and rectal toxicity due to large 
treatment volumes. At the same time, it was recognized that delivering higher doses  to 
the prostate led to better local control [79]. With the introduction of CT-based 3D CRT, 
the dose to the prostate could be increased while simultaneously decreasing the volume 
of irradiated surrounding normal tissue; this led to lowered treatment-related toxicity 
[80, 81]. Image-guided techniques have enabled a further dose reduction in surrounding 
OARs [82].
About the same time as CRT was introduced in the 1980’s, HDR BT for prostate cancer 
was developed in [43, 83, 84]. The BT was typically given as a boost added to standard 
EBRT.
The initial rationale behind using HDR BT was twofold: to be able to accurately treat the 
intended target volume and to utilize the steep dose gradients outside the target to irra-
diate less OAR volume [43]. This would potentially lead to an increased therapeutic ratio. 
Since each BT session is time-consuming (treatment procedure described below), the 
prescribed dose at each fraction was in the range of 8 to 15 Gy.
3.2.3 Fractionation sensitivity of prostate cancer
In 1999, Brenner and Hall published an analysis of the fractionation sensitivity of pros-
tate cancer comparing conventionally fractionated EBRT with low-dose rate BT and 
arrived at an α/β value of 1.5 Gy [85]. Since then, several papers which confirm this result 
have been published [86-88]. The low tumour α/β value makes prostate cancer an ideal 
candidate for hypofractionated radiation therapy and several different treatment regi-
mens have been suggested [89].
3.2.4 Radiation therapy for prostate cancer at the Sahlgrenska 
University Hospital
3.2.4.1 EBRT TEcHniquE
The EBRT technique has basically been the same over the studied period, regardless if 
the treatment has been delivered as primary or salvage EBRT or as part of the EBRT+BT 
combination.
EBRT was individually planned based on CT imaging with the patient in a supine treat-
ment position and with a low concentration of  contrast in the bladder. Using these 
images, the CTV was defined as the prostate gland or, in the case of prostatectomized 
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patients, the post-operative prostatic region. The PTV was defined as the CTV with a 
20-mm margin in all directions except posteriorly, where the margin was 15 mm or 
maximum half the rectal cross-sectional area. For all patients, a three-field 3D CRT tech-
nique with one anterior-posterior and two opposed lateral wedged fields was used. The 
shape of each field was individually optimized by either MLC or by using lead blocks. 
The photon beam quality was in most cases 15 MV, but 11 MV was used as well. The dose 
distribution was calculated with a pencil-beam algorithm and normalized in the centre 
of the PTV so that the 95%-isodose encompassed the PTV. For the primary and salvage 
EBRT groups, prescribed total EBRT dose was in most cases 70 Gy and for the EBRT+BT 
group 50 Gy, both at 2 Gy per fraction.
3.2.4.2 BRAcHyTHERApy TEcHniquE
The HDR BT technique was early adopted at the Sahlgrenska University Hospital – first 
patient treated in 1988 - as
“[a]n alternative technique for the delivery of a high dose to a well defined 
volume with high precision and a rapid decrease of the dose to the sur-
rounding organs is brachytherapy […]” [90]
The regimen consisted of two HDR BT 10-Gy fractions separated by 14 days in the middle 
of 50 Gy EBRT. The total tumour dose was thus 70 Gy given in an OTT of 7 weeks. It 
was recognized that the high dose per fraction delivered to the prostate resulted in an 
advantageous higher tumour effect [91]. Borghede et al. calculated EQD210 = 83 Gy, but 
also hypothesized that the α/β value could be lower due to “an underestimation of the 
repair capacity” and calculated EQD26 = 90 Gy.
The brachytherapy procedure and the delivered dose distributions have been fairly simi-
lar during the studied period. A catheter filled with an air/gel mixture was introduced 
in 2000/2001 to better identify the urethra, and digital storage of ultrasound images 
and dose distributions began in March 2003.
At each brachytherapy session, the patient was placed in lithotomy position (Figure 3.5). 
Transversal images were captured every 5 mm from the base to the apex of the prostate 
using a transrectal ultrasound probe. The CTV was defined as the prostate gland and the 
PTV as the CTV with a margin of 2 mm in the transversal plane. The urethra was iden-
tified using the air/gel mixture and contoured with a diameter of 4 mm on each image. 
The dose distribution was optimized by determining needle positions and dwell times 
for the source within each needle, with the objective to cover the PTV with the pre-
scribed dose (100%) while keeping the dose in the urethra lower than 120%. The treat-
ment was delivered with a high-dose-rate 192Ir source (treatment time 5-15 minutes), and 
the needles were removed immediately after treatment.
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Figure 3.5. Patient in lithotomy position at brachytherapy. Needles have been inserted into the prostate 
through the perineum template and are connected to the afterloader.
3.2.4.3 DOsE DisTRiBuTiOns AnD OAR DVH AcquisiTiOn
For all prostate cancer survivors participating in the study, the EBRT plans were identi-
fied in various databases used 1993-2006. If not already there, the CT images were trans-
ferred to the Eclipse treatment planning environment (Varian Medical Systems, USA) 
where the dose distribution in the original treatment plans were reconstructed from the 
treatment documentation. Ten relevant OARs in the pelvis were identified and consist-
ently delineated. A total of 9501 DVHs were exported as text files, formatted to a suita-
ble format using in-house developed software in JAVA and subsequently transferred to 
MATLAB (MathWorks Inc., USA) for quality control and analysis.
For all survivors treated with the combination of EBRT and BT, basic information on 
number of needles and TRAK were collected. For those treated with BT after March 
2003 ultrasound images and dose distribution information were digitally available and 
additional data on the prostatic urethral mean and maximum doses could be retrieved. 
However, for all survivors treated with the combined therapy, the BT OAR dose distribu-
tions could not be recreated since the OARs of interest were outside the ultrasound field-
of-view. This was addressed in Paper IV.
3.2.4.4 EsTimATiOn OF cOmpOsiTE OAR DOsE DisTRiBuTiOns (pApER iV)
To overcome the issue of missing OAR image information at BT, we suggested a method 
to estimate both the BT dose contribution and subsequently the composite EBRT+BT 
dose distribution. A subset of patients was randomly selected from the study population 
to implement the method. It was then applied to all 376 men treated with EBRT+BT.
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Figure 3.6. Absorbed dose distributions and OAR configuration in sagittal view (excluding the right and 
left femoral heads).  
Top: 50-Gy EBRT;  
Middle: 20-Gy BT reconstructed on the EBRT pre-treatment CT images;  
Bottom: composite absorbed dose distribution, 70-Gy EBRT+BT.
EBRT: 25×2.0 Gy
Sigmoid
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Using this subset, the BT dose distribution and the composite dose distribution as well 
as their corresponding DVHs could be calculated. Since the same CTV was treated for 
both modalities and the dose outside the CTV was minimized to spare the OARs, the 
rationale behind the proposed method was that there could be correlations between 
the dose distributions from the EBRT and the BT (Figure 3.6). Likewise, there could be 
correlations between the DVHs from the EBRT and the BT. This was investigated to esti-
mate four dose distribution descriptors that are useful in NTCP modelling of late effects: 
the near-maximum doses D2cm3 and D2%, the mean absorbed dose and the fractiona-
tion-corrected mean dose. An exhaustive fitting of linear relationships between DV (or 
VD) from the EBRT DVH and the BT dose descriptor in question was performed to obtain 
the linear relationship with the highest coefficient of determination (R2). The process is 
shown in Figure 3.7. In addition to using to DV and VD from the EBRT DVH to estimate 
the BT dose descriptor, its linear relationship (and corresponding R2) with TRAK was 
also calculated.
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Figure 3.7. Illustration of the first step of the proposed method applied. In panel A, the Drv’-EBRT value 
and the D-BT value are calculated for one patient. In panel B, the R2 is calculated for the Drv’-EBRT param-
eter values and the D-BT parameter values for all patients. This is repeated for all rvs and results in the 
R2-graph shown in panel C. The maximum R2 now determines the rv* value and the linear equation that 
best predicts the D-BT parameter.
The average R2 for the investigated combinations of OAR and dose descriptor was 
0.68±0.11 and 38/40 of all R2 was larger than 0.5, that is, it was possible to find a well fitting 
linear relationship between the EBRT DVH and the BT dose descriptor in question.
Table  3.1. The model and associated parameter (cut-off) that best predicted the linear relationship for 
each sought BT parameter and its R2 for the urinary bladder.
Organ at risk Parameter Model Cut-off R2
Urinary bladder D2% (Gy) D  rV=32.0 % 0.69
D2cm3 (Gy) DaV aV=22.0 cm3 0.66
mean dose (Gy) rVD D=31.5 Gy 0.84
mean EQD23 (Gy) rVD D=31.5 Gy 0.78
However, the final goal was the dose descriptor value for the composite EBRT+BT dose 
distribution. The composite mean dose (with or without fractionation correction) as 
A B C
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delivered by two different dose distributions (EBRT and BT in this case) is simply the 
sum of the respective mean doses. For the near-maximum doses the situation is not as 
straightforward. Addition of near-maximum doses by EBRT and BT can only be done 
when they are in the same anatomical location for both treatments. This was investi-
gated by comparing the reference composite near-maximum dose given by the TPS to 
the dose obtained by addition of the EBRT dose (which we know) and the BT dose (which 
we have estimated). For the studied OAR dose distributions, the estimated composite 
near-maximum doses were found to be good approximations of the values calculated 
from the reference DVH (Table 3 in Paper IV). For such situations the composite value 
for any of the dose distribution descriptors for any similarly treated patient, can now be 
estimated from the EBRT DVH and the linear relationship. Furthermore, the  
fractionation-corrected composite dose can also be obtained by correcting the EBRT 
and BT doses for fractionation before addition.
3.2.5 Genitourinary toxicity and questionnaire
Patients undergoing radiation therapy for prostate cancer will as an unavoidable conse-
quence have several pelvic organs irradiated. Among those are the urinary bladder, the 
urethra, the bladder neck and the trigone region, all being OARs from which genitou-
rinary symptoms may originate [92]. It has also been suggested that patient-reported 
toxicity is the better way to report genitourinary toxicity since physician-reported toxic-
ity may underestimate the actual symptom prevalence [92-94]. There is limited knowl-
edge about late genitourinary toxicities with few dose-volume response relationships 
reported [92].
3.2.5.1 sTuDy pOpulATiOn
For the study population in Papers II-V, hospital records were used to identify all men 
that were at most 80 years old and treated with radiation therapy for localized pros-
tate cancer between 1993 and 2006 at the Sahlgrenska University Hospital. The study 
included men who had not been diagnosed with distant metastases, had a sufficient 
knowledge of the Swedish language to read and understand written questions and 
were resident in Sweden at the time of follow-up. Furthermore, using the Swedish Total 
Population Register, 350 population-based controls matched for age and area of resi-
dence were identified; of those, 332 were not previously irradiated in the pelvic region 
and were invited to participate. The Regional Ethical Review Board in Gothenburg 
approved the project. To those who agreed to participate in the study, a questionnaire 
and a pre-stamped return envelope were sent out between February and November 
2008.
Among the 1007 identified prostate cancer survivors, 985 agreed to participate and 874 
(87%) returned a filled-in questionnaire. In the control group, 243 of 332 (73%) returned 
a filled-in questionnaire. The questionnaire contained questions on physical symptoms 
from the pelvic region, demographics, quality of life and comorbidities. For this work, 
a subset of 21 questions reflecting physical symptoms from the genitourinary region 
was used. The symptoms can be categorized into urinary obstruction, irritative toxicity 
and urinary incontinence. Four to seven answering categories were used to determine 
symptom intensity and occurrence where the lowest category corresponded to low 
intensity (e.g. a small amount urinary leakage) or few events (e.g. one event during the 
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last six months) and the highest category to high intensity (e.g. a large amount of uri-
nary leakage) or several events (e.g. at every occasion).
There were three principal groups of prostate cancer survivors: those treated with 
primary EBRT, those treated with a combination of EBRT and HDR brachytherapy 
(EBRT+BT) and those treated with salvage EBRT following prostatectomy (POSTOP). The 
employed radiation treatment techniques for these survivors are described in section 
3.2.4.
3.2.5.2 OuTcOmE OF THE quEsTiOnnAiRE (pApER ii)
Higher symptom rates (prevalence) among survivors compared to controls were found 
for twelve of the 21 investigated genitourinary symptoms: nine in the EBRT group, ten 
in the EBRT+BT group and five in the salvage EBRT group (Table 3.2). The prevalence 
for these symptoms in the control group, i.e. the background rates, varied between 1% 
and 30%. The pattern of symptom rates – the toxicity profile – was similar between the 
primary EBRT and EBRT+BT groups; the difference in prevalence was no more than 5 
percentage points for any of the studied symptom. For the salvage EBRT group, only 
symptoms reflecting incontinence had significantly higher prevalence than the control 
group. Also, in this group, the prevalence of symptoms reflecting urinary flow was sig-
nificantly lower than for the control group (i.e. the actual removal of the prostate gland 
seem beneficial in this regard).
Table 3.2. Prevalence for 3 of the 21 investigated genitourinary symptoms among the prostate cancer 
survivors treated with EBRT, EBRT+BT or salvage EBRT and the non-pelvic-irradiated control men. Preva-
lence ratios for the treated groups with respect to controls.
Treatment group 
Symptom
EBRT 
n./N. (%) 
PR (95% CI)
EBRT+BT 
n./N. (%) 
PR (95% CI)
POSTOP 
n./N. (%) 
PR (95% CI)
CONTROL 
n./N. (%) 
PR (95% CI)
5. Sensation of bladder being non-empty after 
urinating on half or more of the occasions
62/297 (21) 
1.4 (1.0*-2.1)
81/368 (22) 
1.5 (1.1-2.2)
28/196 (14) 
1.0 (0.6-1.6)
35/241 (15) 
Reference
15. Urethral pain when urinating on half or 
more of the occasions
10/298 (3) 
1.4 (0.5-3.7)
23/368 (6) 
2.5 (1.0**-6.1)
8/197 (4) 
1.6 (0.6-4.6)
6/242 (2) 
Reference
16. Weekly urinary leakage, more than a few 
drops 
68/298 (23) 
2.0 (1.3-3.0)
67/368 (18) 
1.6 (1.0**-2.4)
66/196 (34) 
2.9 (2.0-4.3)
28/242 (12) 
Reference
POSTOP = salvage radiation therapy after surgical prostatectomy; PR = prevalence ratio; CI = confidence interval. 
*, lower 95% CI below 1.0. 
**, lower 95% CI above 1.0.
The temporal pattern of symptom occurrence varied, but the prevalence generally 
changed moderately over time. For all symptoms but one (nocturia), survivors with 
time to follow-up shorter than 3 years had a higher symptom rate than survivors with 
time to follow-up between 4 and 5 years.
3.2.6 Urethral pain (Paper III)
The question on urethral pain (question 15) had a statistically significant higher prev-
alence in the EBRT+BT group than in the control group and it was also notably higher 
than in the primary EBRT group. This in combination with the exposed location of 
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the urethra inside the target volume led to a more thorough analysis of the non-treat-
ment-related and treatment-related factors impacting the occurrence of urethral pain 
after radiation therapy.
The (translation of the) studied question is “The last 6 months, have you felt burning pain 
in the urethra when urinating?” with the answering categories “No”, “Yes, less than half 
of the times”, “Yes, about half of the times”, “Yes, more than half of the times”, and “Yes, 
always”. The endpoint was defined as “No” versus any occurrence. 
The dose distribution along the urethra is schematically shown in Figure 3.8. The part of 
the urethra inside the prostate (the prostatic urethra) will receive a homogeneous dose 
distribution with a mean absorbed dose close to the prescribed dose for the EBRT treat-
ment. Extracting data from the urethral BT DVH for all survivors having available dose 
distribution and image information (survivors treated after March 2003) showed that 
also the BT urethral dose distribution was fairly homogeneous. That the average mean 
dose was 106±3% (1 SD) and the average maximum dose was 111±3% (1 SD) of the pre-
scribed BT dose. Survivors who had undergone radical prostatectomy have no prostatic 
urethra and were excluded from the analyses.
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Figure 3.8 Top: Schematic description of the urethral dose distribution in cranio-caudal direction for 
70-Gy EBRT and 70-Gy EBRT+BT. The prostatic urethral absorbed dose from EBRT is equivalent to the pre-
scribed dose and the absorbed dose from BT is 106% of the prescribed dose.  
Bottom: A transversal ultrasound image of the prostate with the prostate (CTV) in red, PTV in cyan, ure-
thra in dark green, and expanded urethra in light green. Shown isodoses are 10 Gy (prescribed dose) in 
white and 12 Gy in yellow.
The prevalence of urethral pain was 24% among the EBRT+BT survivors compared to 
13%, 11% and 12% among the primary EBRT, salvage EBRT and non-irradiated controls, 
respectively. Time to follow-up was the only non-treatment related factor that affected 
the prevalence of urethral pain for non-surgically-treated survivors. For survivors 
treated with 70-Gy EBRT+BT there seemed to be symptom relief over time: 32% versus 
19% for time to follow-up shorter and longer than 3 years, respectively (Figure 2 in Paper 
III).
The time effect was taken into account by performing analyses separately for short and 
long follow-up (<3.0 years and ≥ 3.0 years). The evaluations were performed for the 
ur
et
hr
al
 a
bs
or
be
d 
do
se
 [G
y] EBRT+BT: 25×2.0+2×10.0 Gy
EBRT+BT: 35×2.0 Gy
EBRT+BT: 25×2.0 Gy
BT: 2×10.0 Gy
distance from the base of the prostate [cm]
42
mean urethral dose without fractionation correction and with fractionation-correction 
using the LQ model with α/β=3 Gy and the LQ-L model with α/β=3 Gy and dt=8 Gy. For 
absorbed dose, no relationship between urethral dose and pain was found for either 
short or long time to follow-up. Relationships between irradiation and pain for long 
and short follow-up was found for LQ corrected doses when α/β=3 Gy was used, and no 
other choice of α/β did significantly improve this fit (Figure 3.9). For the LQ-L model, a 
dose-response relationship was found for long follow-up, but not for short. Using lower 
α/β or a higher dt would however have confirmed a dose-response relationship in this 
situation as well.
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Figure 3.9. Prevalence of urethral pain for the different treatment groups stratified by time to follow-up. 
Top: time to follow-up shorter than 3 years. Bottom: time to follow-up longer than 3 years. The vertical 
error bars show the 68% CI for the observed prevalence.
For survivors treated with 70-Gy EBRT+BT, we also investigated if TRAK, number of 
needles, and irradiated length of the urethra was associated with an increased symp-
tom risk. Specifically the irradiated urethral length was of interest since an association 
would point toward a volume effect. However, neither of the investigated factors was 
found to influence the occurrence of urethral pain.
Given sufficient time for symptom relief, the urethra has a high tolerance to irradia-
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tion. Equieffective doses EQD23 below 90 Gy seem well tolerated, that is, the prevalence 
among survivors was equal to the background rate among non-irradiated individuals. 
The exposed anatomical location of the urethra makes it difficult to reduce the urethral 
dose without simultaneously reducing the tumour dose (and potentially jeopardiz-
ing tumour control), especially for EBRT techniques. For HDR brachytherapy, however, 
there are more possibilities for urethral dose reductions with only a small effect on the 
tumour dose, but it is also easier to irradiate the urethra with an unnecessarily high 
dose.
3.2.7 NTCP modelling of genitourinary toxicity (Paper V)
In this work, we used an NTCP modelling approach to further investigate the 21 genito-
urinary symptoms reported in Paper II. We used treatment and symptom data for 641 
men treated with either primary EBRT or EBRT+BT as well as symptom data collected 
from 242 men in the control group.
The dose descriptors used for modelling purposes was 1) the prescribed dose, 2) the 
bladder mean dose and 3) the bladder near-maximum dose defined as D2cm3 and D2% as 
well as EQD23 versions of 1-3 using the LQ model and α/β=3 Gy. The prescribe dose can 
be considered representative of the urethral dose and the bladder near-maximum dose 
is representative of both the trigonal region dose and the bladder neck dose. Symptoms 
were primarily used with the cut-offs that were deemed clinically relevant. We also 
examined secondary cut-offs at one level above and one level below the primary cut-off 
to balance high background rates against too few events among survivors.
To establish that a dose descriptor was associated with the symptom, two criteria had 
to be fulfilled: the descriptor had to be statistically significant in logistic regression and 
the symptom prevalence among survivors had to be significantly higher than among 
controls. Analyses were separately performed for the group of survivors treated with 
primary EBRT and for the group treated with EBRT+BT. For survivors treated with 
EBRT+BT, the method in Paper IV was used to estimate composite doses. However, 
assuming the same amount of bladder filling, 300 cm3, at every BT irradiation, all sur-
vivors were assigned the same mean urinary bladder dose contribution from BT: 1.6 Gy 
per 10-Gy fraction (absorbed dose), 2.0 Gy per 10-Gy fraction (EQDmean23), and 3.7 Gy per 
15-Gy fraction (EQDmean23). This assumption was founded in the consequences by stand-
ard routines foregoing BT where the urinary bladder was emptied before planning and 
needle insertion resulting in similar bladder filling between patients at treatment.
The only symptom found to be relevant for NTCP modelling was urinary incontinence 
(question 16 in Table 3.2). Among the men treated with primary EBRT, both urinary 
bladder mean dose and fractionation-corrected urinary bladder mean dose correlated 
with this symptom.
Using survivors treated with primary EBRT in 2-Gy fractions (n=241), dose-response 
curves were estimated, Figure 3.10. The dose-response curve for fractionation-corrected 
mean dose (bottom panel) was parameterized by EQD23 = 89.0 Gy and γ50= 1.06 using 
a background rate of 7% for EBRT survivors receiving their treatment with a varying 
number of 2-Gy fractions. This means that if the EQDmean23 can be kept below 35 Gy, the 
excess risk is estimated to less than 5%.
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Figure 3.10. Top: Dose-response curve for prevalence of incontinence using mean urinary bladder dose 
and a 7% symptom background rate.  
Bottom: Dose-response curve for prevalence of incontinence using mean fractionation-corrected urinary 
bladder dose and a 7% symptom background rate. The mean doses have been stratified into six bins; the 
vertical error bars show the 68% CI for the prevalence.
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4. DISCUSSION
The presented results in Papers I-V cover methodological and practical issues such as radiobiologically consistent mathematical descriptions of dose-response 
curves, dose-distribution estimation in situations with limited treatment information 
and how to manage situations where non-treatment-related factors contribute to the 
studied toxicity. These principles were applied in two different clinical datasets from 
patients treated at the Sahlgrenska University Hospital. In Paper I we found dose- and 
volume-response relationships for radiation-induced rib fracture after hypofraction-
ated SBRT. In Papers II, III and V we evaluated and compared genitourinary toxicity 
after conventional and hypofractionated radiation therapy for prostate cancer and also 
found dose-response relationships for urethral pain and urinary incontinence.
4.1 Radiation-induced rib fracture after 
hypofractionated SBRT for NSCLC (Paper I)
4.1.1 NTCP modelling of radiation-induced rib fracture
The dataset in this study has several strong features. All treatments were planned based 
on CT imaging in a group of consecutive patients and the high-precision patient setup 
in the stereotactic body frame meant that the calculated DVHs can be considered accu-
rate descriptions of the delivered rib dose distributions. The studied endpoint could be 
thoroughly determined: the status of all ribs in the chest could be evaluated with high 
sensitivity and specificity using the frequently performed CT scans. Furthermore, the 
status of the ribs prior to irradiation was available in the pre-treatment scan. 
One drawback of the study is the limited number of rib fractures (n=13) which leads 
to parameter estimates with wide confidence intervals. Another issue is the limited 
follow-up time in some patients; those without rib fracture with short follow-up may 
present with a fracture at a later time. This would lead to an underestimation of the risk. 
A great majority of rib fractures occur within 4 year after treatment and the median fol-
low-up among the non-fractured ribs in our study was 27 months [95-97]. 
The dose distribution was calculated with a pencil-beam algorithm. This is known to 
give erroneous results in lung tissue [98-100]; we estimated its accuracy in the ribs to 
be within 5%. Furthermore, the pencil-beam algorithm calculates the absorbed dose to 
water in the medium in question and not the absorbed dose to the medium; the differ-
ence is about 10% in cortical bone [101].
This was, to our knowledge, the first paper that used clinical data for NTCP modelling 
of late effects in highly hypofractionated radiation therapy for any endpoint. Several 
papers on radiation-induced rib fracture after hypofractionated radiation therapy have 
been published since, although only a few with endpoint and OAR definition similar to 
ours [95-97]. The treatment techniques in the these studies varies, photon EBRT in four 
fractions to 48 Gy [95], proton EBRT in six fractions to 60 Gy [96] and photon EBRT in 
three-four fractions to 30-60 Gy [97]. The conclusions are overall analogous to ours 
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as the high-dose/small-volume region of the DVH correlates stronger with rib fracture 
than a low dose in a large volume.
4.1.2 Dose-response curves for hypofractionated radiation therapy
Radiobiologically consistent dose-response curves to be used when a treatment is deliv-
ered with a fixed number of fractions were derived using α/β from the LQ model to 
quantify the fractionation sensitivity. As purely mathematical entities they contain no 
uncertainties per se, but it cannot be guaranteed that they accurately describe actual 
clinical dose-response relationships. When fitted to the rib fracture dataset, all values 
of α/β resulted in equally good fits. This may seem somewhat surprising, but it is actu-
ally advantageous since we do not need to know the correct α/β value to estimate the 
dose-response curve parameters. When reporting results for dose-response relation-
ships, or when applying dose-response curves reported in the literature, it is important 
to be aware of that incorrect handling of fractionation-effects may lead to incorrect 
results. Specifically, both the position (D50) and the steepness (γ50) are affected by the 
fractionation effect.
4.2 Genitourinary toxicity after radiation 
therapy for prostate cancer (Papers II-V)
4.2.1 Questionnaire and measurement of toxicity
The measurement of genitourinary toxicity for prostate cancer survivors and an age- 
and residency-matched control population were performed with a postal-based ques-
tionnaire. The questions were developed to measure clearly defined atomized symp-
toms. The symptom rates (prevalence) among prostate cancer survivors were compared 
to the background rates among the non-pelvic-irradiated men in the control group 
which assisted in deciding whether a symptom could be attributed to the treatment or 
was due to other factors.
The strengths of this study are that the investigation was performed in an unselected 
large population with long follow-up and a high response rate (87%), that atomized 
patient-reported symptoms were used, and that symptom background rates from a pop-
ulation-based, matched control group could be used for comparison [92, 93]. We could 
reconstruct the EBRT urinary bladder DVHs for 96% (841/874) of the study participants. 
The mean bladder dose contribution from BT, however, could not be reconstructed from 
treatment documentation but had to be estimated.
We lack information on pre-treatment morbidity which previously has been shown to 
be associated with the risk of late genitourinary toxicity [92, 102]. However, pre-treat-
ment prostate enlargement or the presence of cancer may cause this morbidity, which is 
not seen among ”healthy” controls [103]. Therefore, one may assume that the symptom 
rates in population-based controls represent an optimal level for post-treatment com-
parison.
Interpretation of the effect measures was used with epidemiological methods as 
adapted to the cancer survivorship field by the hierarchical step-model for causation 
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of bias [50]. According to this, there are different sources of error that can threaten the 
validity of a study such as confounding, misrepresentation and misclassification.
4.2.1.1 cOnFOunDing
A confounder is a variable that is casually related to the independent variable (X) and 
the dependent variable (Y). If not adjusted for in the analyses, a confounder can pro-
duce a mis-estimation of the strength of association between X and Y. We can only eval-
uate the potential confounders for which we have data. In this study, the questionnaire 
contained questions on possible confounders such as age, body mass index (BMI), and 
comorbidities to enable adjustment of these factors in the analyses if necessary.
Age is a potential confounder for OAR dose (X) when genitourinary toxicity (Y) is evalu-
ated. Age-adjusted prevalence ratios were calculated for the genitourinary toxicity pro-
files in Paper II, but did not effect the overall conclusions.
4.2.1.2 misREpREsEnTATiOn
Misrepresentation occurs when participants differ from non-participants in some 
crucial way. For instance, if men experiencing late genitourinary symptoms are non-
participants to a higher degree than men not experiencing these symptoms, we will 
underestimate the symptom prevalence. If non-participation due to symptom occur-
rence differs between the survivors and the controls, the calculated prevalence ratio will 
be affected. The information from non-participants will remain unknown and a large 
loss to follow-up will seriously affect the validity of the effect measures. The only way to 
minimize misrepresentation is to keep the participation rate as high as possible.
In this study, 874 of 1007 (87%) identified men returned a filled-in questionnaire; among 
the controls meeting the inclusion criteria, 243 of 332 (73%) returned a filled-in ques-
tionnaire.
4.2.1.3 misclAssiFicATiOn
Misclassification is the same as measurement error and can concern either the exposure 
or the outcome under study. There are two types of misclassifications: non-differen-
tial and differential. Non-differential misclassification occurs when the probability for 
committing a measurement error is the same for all participants in a study irrespective 
of exposure or outcome. Committing such errors will generally shift the prevalence 
ratio towards 1, i.e. towards no effect. Differential misclassification occurs when the 
probability to commit a exposure or outcome measurement error is different in various 
groups of the study population. Committing such errors will affect the effect measure 
in unpredictable ways.
Great care was taken in the construction of the questionnaire (for instance through face val-
idation) to minimize the risk of misclassification. However, the participants can introduce 
misclassification when trying to remember a symptom and report an overestimated or under-
estimated symptom occurrence.  Mistakes can also be made during the manual transferral of 
the filled-in questionnaire into digital format. Differential misclassification may be an issue in 
the estimation of mean urinary bladder doses in Paper V where the BT mean dose contribution 
had to be estimated using methods from Paper IV. This potential source of misclassification 
was addressed by performing analyses separately in the EBRT and EBRT+BT groups.
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4.2.2. Survey of genitourinary late toxicity (Paper II)
This was a survey of the collected questionnaire data. Survivors were stratified accord-
ing to treatment modality and prevalence and prevalence ratios with respect to controls 
were calculated for each group.
We found that survivors in the EBRT and EBRT+BT groups had similar toxicity profiles. 
For survivors treated with salvage EBRT, symptoms reflecting incontinence were the 
most common; this is a well-known toxicity after prostatectomy although some cases 
can be attributed to the EBRT [104-106]. Symptom background rates, or occurrences of 
symptoms in a population similar to the one under consideration, become more impor-
tant to acknowledge when estimating risks for “less severe” toxicities. If the background 
rate is substantial and overlooked, the toxicity induced by the treatment will be overes-
timated. Modifying the dose distribution may then lead to a jeopardized tumour con-
trol without actually lowering the symptom risk as much as anticipated.
The reports on temporal pattern of genitourinary symptoms are diverging in the liter-
ature. Symptoms reflecting obstruction, urgency and frequency have been reported to 
remain at the same level with time [107, 108] whilst incontinence is typically reported 
to increase [105, 109, 110]. In our study, the symptom prevalence tended to be higher the 
first years after radiation therapy and then decreased. The exception was for urinary 
frequency that increased with longer time to follow-up. Genitourinary toxicity has pre-
viously been reported to decrease over time and it has also been suggested that the actu-
arial incidence may overstate the toxicity in the long-term perspective [110].
4.2.3 Urethral pain (Paper III)
After observing that burning urethral pain during urination was a symptom that was 
more prevalent among survivors treated with EBRT+BT than among primary EBRT 
survivors, we investigated how treatment-related and non-treatment-related factors 
impacted the prevalence.
We found that prostate cancer survivors treated with EBRT+BT reported a higher occur-
rence of urethral burning pain during urination compared to those treated with pri-
mary and salvage EBRT. The symptom was more common among men with 3 years to 
follow-up compared to men with more than 3 years to follow-up. This observation of 
symptom relief is in line with previous reports for similar treatments [110].
We demonstrated dose-response relationships where higher urethral EQD23 values cor-
responded to a higher occurrence of pain explaining the differences in prevalence of 
pain for the various primary EBRT and EBRT+BT fractionation regimens. Our dataset 
is to about 85% comprised of  survivors treated with either 35×2.0-Gy primary EBRT or 
25×2.0+2×10.0-Gy EBRT+BT, that is, we have relatively little symptom risk information 
for other dose levels. This lack of data for many different urethral doses has the effect 
that we could not isolate a small range of α/β values that better describe the observed 
outcome, although we could conclude that using fractionation-corrected dose gave 
better fits than using absorbed dose.
The symptom rate among survivors treated with primary 70-Gy EBRT (regardless of 
time to follow-up) was no different than the symptom rate among the controls. Waiting 
for symptom relief to occur during three years after treatment, even EQD23=90 Gy seem 
to be well tolerated. One observation is that among survivors that were treated with 
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‘double hypofractionation’, 13×3.1+15.0-Gy EBRT+BT, 5/6 (83%) reported urethral pain. 
The time to follow-up among those men were short, 1.3-2.0 years, and this prevalence 
can be compared to 9/23 (39%) among survivors treated with 70-Gy EBRT+BT having the 
same time to follow-up (prevalence ratio=2.1; 95% CI 1.1-4.0). There was an advantage 
of having access to symptom data from non-pelvic-irradiated men. The 10% prevalence 
among survivors treated to 70-Gy primary EBRT - similar to the background rate of 11% - 
could otherwise easily been attributed to the treatment.
4.2.4 Composite dose distributions for combined EBRT and BT (Paper IV)
For all 373 survivors treated with the combination of EBRT and BT, none of the ten 
defined OARs in the pelvis were in the field-of-view of the ultrasound probe during BT. 
This meant that we had neither direct information of the dose contribution from the 
BT nor of the composite dose distribution. The purpose of this study was to suggest and 
use a method that in a time-efficient way can estimate the brachytherapy dose contri-
bution as well as the composite dose distribution to facilitate NTCP modelling. The dose 
descriptors judged to be of interest in the modelling of late effects was the mean dose, 
the fractionation-corrected mean dose, and the near-maximum doses D2cm3 and D2%.
The utility of the method depends on two things: can it be successfully implemented 
and are the estimated doses good approximations of those actually given at treatment? 
In the dataset explored in this work, high R2 values were obtained in most of the OAR 
and BT parameter combinations and the composite dose descriptor values were judged 
to be useful as well. The steep dose gradient outside the PTV delivered by the BT has two 
main consequences. First, OARs located far from the PTV are located in a region with a 
shallow dose gradient and will also receive a small dose contribution; a mis -estimation 
of this small contribution will not be critical. Second, the OARs close to the PTV are 
located in a region with a steep dose gradient and will also be subject to a higher BT 
dose; a mis-estimation in this case will introduce a larger error in terms of absolute 
dose. Also, for OARs close to the PTV, the steep dose gradient will have the consequence 
that differences in the PTV- and OAR-definitions will greatly affect the shape of the cal-
culated DVHs.
Furthermore, if the determined relationship between the EBRT and BT DVH parameters 
is to reflect what actually is delivered by BT, there must be a similarity in OAR and PTV 
configuration at both treatments. This must be judged on an OAR-to-OAR basis.
4.2.5 NTCP modelling of genitourinary toxicity (Paper V)
The purpose of this study was to perform NTCP modelling of genitourinary toxicity after 
radiation therapy for prostate cancer.
We found a dose-response relationship between urinary bladder mean dose (with or 
without fractionation correction) and urinary incontinence among survivors treated 
with primary EBRT. We believe that the reasons for not finding this relationship 
between mean bladder dose and incontinence in the 70-Gy EBRT+BT group may be 
explained by some additional effect by the BT or that the 5% excess risk was too small 
to detect. However, it is worth noting that on a group level, the model predictions for 
the EBRT+BT group with and without the estimated BT contribution were 13% and 14%, 
respectively; both close to the observed incontinence prevalence (12%) in the EBRT+BT. 
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Interestingly, the high prevalence for the 60-64+10-Gy EBRT+BT regimen (7/24, 29%) and 
the low incontinence prevalence in the 58-60+15-Gy EBRT group (2/38, 5%) are not satis-
factorily explained by the mean urinary bladder dose; this needs to be further investi-
gated.
The urinary bladder is a highly flexible organ and its size changes with filling. For EBRT, 
this means that unless a patient has the same amount of filling at a specific fraction as 
he had at the pre-treatment CT, the calculated DVH will not be a good representation 
of a delivered dose distribution at that fraction. However, if pre-treatment CT imaging 
captures the average bladder filling expected over the whole course of radiation therapy, 
both the mean and near-maximum doses can be considered reasonably accurate. 
4.3 General remarks
The LQ model is currently the established way to take the fractionation effect into 
account. However, currently we lack clinical evidence for the validity of the LQ model at 
high doses per fraction but even if the model turns out to be valid, we may not know the 
relevant α/β values. This impairs our ability to design optimal hypofractionated treat-
ment regimens where both tumour control and normal tissue toxicity are considered.
How the lack of knowledge of α/β affects NTCP modelling of late toxicities in fraction-
ated radiation therapy depends on the treatment regimen. If all patients are treated 
with the same number of fractions and each patient is treated with the same dose per 
fraction throughout the treatment, dose-response curve parameter estimations are 
insensitive to the value of α/β; this was utilized in Paper I. This is in contrast to the 
dose-response relationship for urethral pain in Paper III where the urethral dose for the 
combination of EBRT and BT was delivered with different doses per fraction. Conse-
quently, fractionation-corrected doses had to be used to assess how irradiation affected 
the prevalence of urethral pain leading to α/β-dependent estimates of tolerance doses.
Although the fractionation sensitivity may be a major concern for NTCP modelling in 
hypofractionated radiation therapy, the volume effect also needs to be considered. In the 
analysis of rib fractures in Paper I, cut-off descriptors were used to summarize the DVH 
into one value representing the entire dose distribution. The high-dose/small-volume 
region was associated stronger with rib fracture than a low dose in a large volume indi-
cating that ribs have a small volume effect. In the analysis of urethral pain in Paper III, 
the BT urethral dose distributions were fairly homogeneous, i.e. there was little difference 
between the mean and maximum dose making it difficult to detect any potential volume 
effects. The length of irradiated urethra was also examined, but no relation between the 
irradiated length and occurrence of pain was found. In the search for dose-response rela-
tionships of various genitourinary symptoms in Paper V, four dose distribution param-
eters representing the dose distribution in OARs hypothesized to be relevant for genitou-
rinary toxicity, were used (or eight, since each parameter was analysed with and without 
fractionation correction). The urinary bladder was the only OAR where we evaluated 
potential volume effects. We found an association between the urinary bladder mean 
dose and the prevalence of urinary incontinence, but not for the near-maximum dose.
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5. CONCLUSIONS AND 
FUTURE PERSPECTIVE
5.1 Conclusions
In this thesis, the focus has been on modelling late toxicity following hypofractionated 
radiation therapy. The main conclusions are:
 ◆ Radiobiologically consistent mathematical expressions of dose-
response curves in a treatment situation with a fixed number of frac-
tions must consider the fractionation sensitivity; such equations were 
derived in Paper I using α/β from the LQ model. It was shown that 
although an α/β value needed to be included, equally good fits could 
be achieved regardless which value was chosen. However, when 
applying a known dose-response curve for another fractionation reg-
imen, both D50 and γ50 are affected and must be recalculated to fit the 
new situation.
 ◆ The risk of radiation-induced rib fracture after hypofractionated 
SBRT could be estimated using dose-response curves and informa-
tion from the DVH. The high-dose/small-volume region of the DVH 
was more strongly associated with rib fracture than a low dose in a 
large volume.
 ◆ A time-efficient method to estimate the composite mean and 
near-maximum doses in ten OARs in the pelvis after combined pros-
tate EBRT and HDR BT was proposed and implemented. The steep 
dose gradients delivered by BT will sometimes make estimations for 
OARs close to the PTV uncertain while estimations for OARs further 
away will be more robust.
 ◆ The toxicity profiles for genitourinary symptoms were similar for 
prostate cancer survivors treated with conventionally fractionated 
EBRT and those treated with a combination of conventionally frac-
tionated EBRT and HDR BT. The corresponding symptom rates among 
non-pelvic-irradiated control men varied substantially.
 ◆ Prostate cancer survivors with 3 years to follow-up reported ure-
thral pain more frequently than survivors with more than 3 years to 
follow-up. A relationship where higher urethral EQD23 corresponded 
to higher prevalence of pain was demonstrated; no such relationship 
was seen for absorbed dose. 
 ◆ The mean urinary bladder dose, with or without fractionation cor-
rection, was a significant predictor of incontinence among prostate 
cancer survivors treated with primary EBRT.
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 ◆ Having access to symptom data from non-pelvic-irradiated men was 
advantageous for modelling of genitourinary toxicities: symptom 
rates among survivors could be set in relation to the background rate 
preventing us from overestimating the effect of irradiation.
5.2 Future perspective
There is now a substantial amount of available data on radiation-induced rib fracture 
after hypofractionated SBRT. These data have large variation in both number of deliv-
ered fractions and in dose per fraction. If these data were pooled, they may give some 
insight into the validity of the LQ model at high doses per fraction for this late toxicity. 
Hypofractionated radiation therapy regimens are becoming an established treatment 
for localized prostate cancer and they have the potential to deliver a high equieffective 
dose using EBRT or HDR BT. It is reasonable to believe that both hypofractionated EBRT 
and HDR BT will continue to be used with image-guided techniques and small CTV-to-
PTV margins, resulting in small volumes of normal tissue irradiated to high doses and 
also a low mean urinary bladder dose. However, normal tissues within the PTV will be 
subject to a non-ideal situation of high doses at high doses per fraction. Current knowl-
edge about which OAR (or group of OARs) that is responsible for a specific genitourinary 
late toxicity is limited. This situation can only be improved by collecting and analysing 
high-quality toxicity and dose distribution data.
Radiation therapy delivered by different modalities or by multi-phase EBRT results 
in an OAR being irradiated with different dose distributions. This has the effect that 
even if the voxel-wise sum of the absorbed dose distributions and its corresponding 
DVH can be calculated by the TPS, this DVH cannot be used to correct for fractionation 
effects. However, we are approaching a situation where commercially available TPSs can 
add dose distributions from different modalities and calculate DVHs for the fractiona-
tion-corrected dose distribution. This will most likely be used in both the optimization 
of treatment plans and for NTCP modelling purposes.
Dose distributions in the OARs from today’s hypofractionated radiation therapy are 
delivered with high doses per fraction and may be exceptionally inhomogeneous. It 
should be recognized that the two most widely used NTCP models, the LKB model and 
the relative-seriality model, have not yet been fitted to clinical data under those circum-
stances. Furthermore, although both may be used with fractionation-corrected DVHs, 
we do not know if they will result in reasonable parameter estimates when the input 
data looks decidedly different than before. This needs to be further investigated.
Prostate cancer, NSCLC, cervical cancer, and liver cancer are but a few examples of 
cancer types that can be expected to increasingly be treated with curative intent utiliz-
ing hypofractionated radiation therapy. As we continue to increase local control and 
overall survival for these patients, knowledge about how to design fractionation regi-
mens and dose distributions that offer an optimal compromise between tumour control 
and toxicity becomes essential to maintain the quality of life both in the short term and 
long perspective
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